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Abstract
Since the publication of the Society for Immunotherapy of
Cancer’s (SITC) original cancer immunotherapy biomarkers
resource document, there have been remarkable
breakthroughs in cancer immunotherapy, in particular
the development and approval of immune checkpoint
inhibitors, engineered cellular therapies, and tumor
vaccines to unleash antitumor immune activity. The most
notable feature of these breakthroughs is the achievement
of durable clinical responses in some patients, enabling
long-term survival. These durable responses have been
noted in tumor types that were not previously considered
immunotherapy-sensitive, suggesting that all patients
with cancer may have the potential to benefit from
immunotherapy. However, a persistent challenge in the
field is the fact that only a minority of patients respond
to immunotherapy, especially those therapies that rely
on endogenous immune activation such as checkpoint
inhibitors and vaccination due to the complex and
heterogeneous immune escape mechanisms which can
develop in each patient. Therefore, the development of
robust biomarkers for each immunotherapy strategy,
enabling rational patient selection and the design of
precise combination therapies, is key for the continued
success and improvement of immunotherapy. In this
document, we summarize and update established
biomarkers, guidelines, and regulatory considerations for
clinical immune biomarker development, discuss well-
known and novel technologies for biomarker discovery
and validation, and provide tools and resources that can
be used by the biomarker research community to facilitate
the continued development of immuno-oncology and aid in
the goal of durable responses in all patients.

Overview
In the Introduction to biomarkers for the
immunotherapy of cancer section, we introduce the cancer immunotherapy revolution from the standpoint of biomarkers and
their roles in predicting clinical outcome
or adverse events, as well as in quantifying
antitumor immune responses. We discuss
best practices for biomarker development,

validation, and harmonization of data, and
technical considerations for sample collection and reporting of data. Finally, we review
recent biomarker discovery literature and
regulatory considerations for developing
diagnostics. These topics are divided into the
following elements:
►► Background.
►► Recently approved cancer immunotherapies—a breakthrough.
►► Biomarkers of immune response and clinical outcome in patients with cancer.
►► Biomarkers of immune-
related adverse
events and correlation with clinical
response.
►► Quantifying the antitumor immune
response.
►► The development and validation of immunotherapy biomarkers.
►► Data harmonization efforts for biomarker
discovery.
►► Sample collection: technical considerations for processing, storage, and
shipment of tumor samples for immunological studies.
►► Reporting of biomarker data in clinical
trials and publications.
►► Novel biomarker discovery: immunotherapy biomarker useful literature
review.
►► Regulatory
agency
guidelines
for
diagnostics.
In the New and emerging technologies for
biomarker discovery section, we focus on
technology platforms, especially those that
are new and emerging, for use in biomarker
discovery. These are grouped by the type of
cellular target. First, we consider nucleic
acid-
based platforms, including genomic,
microbiome, mitochondrial genome, epigenetic, transcriptomic (including single-cell),
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and PCR/hybridization techniques. Second, proteomic
biomarkers, ranging from ELISA to mass cytometry,
are reviewed, along with imaging technologies that can
analyze spatial context in tumor biopsies. Software tools
for all these platforms are reviewed. Finally, we review in
vivo imaging platforms and metabolic biomarkers. These
topics are divided into the following elements:
►► Genomic biomarker discovery.
►► Microbiome sequencing.
►► Mitochondrial genome arrays.
►► Epigenomic biomarker discovery.
►► Transcriptomic biomarker discovery.
►► Single-cell gene expression analysis.
►► Hybridization and PCR-
based gene expression
platforms.
►► Proteomic
biomarkers
discovery:
detection
techniques.
►► Proteomic biomarkers discovery: target identification
and immunomonitoring.
►► Immune contexture biomarker discovery.
►► Software and tools for data analysis.
►► In vivo imaging (non-invasive and whole body).
►► Predictive
metabolic
biomarkers
in
tumor
immunotherapy.
We conclude with an extensive table of online
resources, including links to consortia and regulatory
agency websites, databases, online software tools, and
clinical trial registries. Resources include:
►► Cancer Immune Monitoring and Analysis Centers/
Cancer Immunologic Data Commons network
(CIMAC/CIDC).
►► Partnership for Accelerating Cancer Therapies (PACT).
►► Links to Food and Drug Administration (FDA)
biomarker approval.
►► Public databases.
►► Transcription factors binding sites prediction software.
►► Tools for neoantigen prediction.
►► Clinical trial registries (CTRs).
Introduction to biomarkers for the immunotherapy
of cancer
Background
The Society for Immunotherapy of Cancer (SITC) has
extensively documented the importance of biomarkers
for cancer immunotherapy through symposia and workshops, and the SITC Biomarkers Committee has been
involved in the publication of a number of technology
primers and white papers.
Workshop reports
SITC 2018 workshop report: immuno-
oncology
biomarkers: state of the art.1
►► Immunotherapy biomarkers 2016: overcoming the
barriers.2
►►

White papers
Validation of biomarkers to predict response to
immunotherapy in cancer: volume I—pre-analytical
and analytical validation.3

►►

2

►►

►►
►►
►►
►►

►►

Validation of biomarkers to predict response to immunotherapy in cancer: volume II—clinical validation
and regulatory considerations.4
Identifying baseline immune-
related biomarkers to
predict clinical outcome of immunotherapy.5
Systematic evaluation of immune regulation and
modulation.6
Novel technologies and emerging biomarkers for
personalized cancer immunotherapy.7
Society for Immunotherapy of Cancer clinical and
biomarkers data sharing resource document: Volume
I—conceptual challenges.8
Society for Immunotherapy of Cancer clinical and
biomarkers data sharing resource document: Volume
II—practical challenges.9

Technology primers
Immune
monitoring
technology
primer:
immunosequencing.10
►► Immune monitoring technology primer: the enzyme-
linked immunospot (Elispot) and fluorospot assay.11
►► Immune monitoring technology primer: single cell
network profiling (SCNP).12
►► Immune monitoring technology primer: flow and
mass cytometry.13
►► Immune monitoring technology primer: clinical validation for predictive markers.14
►► Quantitative real-
time PCR assisted cell counting
(qPACC) for epigenetic-based immune cell quantification in blood and tissue.15
16
►► nCounter PanCancer Immune Profiling Panel.
►► Immune monitoring technology primer: protein
microarray (‘seromics’).17
18
►► Multiplexed tissue biomarker imaging.
►► Immune monitoring technology primer: immunoprofiling of antigen-stimulated blood.19
►► Immune
technology primer: whole exome
sequencing for neoantigen discovery and precision
oncology.20
►► Biomarkers immune monitoring technology primer:
Immunoscore Colon.21
The current source document, which was developed by
the SITC Biomarkers Committee of 2018–2019 to support
biomarker research for various immunotherapeutic strategies, is an update from the cancer immunotherapy
biomarker resource document published by SITC in
2011.
►► SITC/iSBTc cancer immunotherapy biomarkers
resource document: online resources and useful
tools - a compass in the land of biomarker
discovery.22
Since then, there have been revolutionary advances
in the cancer immunotherapy field, highlighted by the
successful clinical development of immune checkpoint
inhibitors (ICIs) and genetically engineered cellular
therapies. The management of a growing list of cancers
has been transformed by immunotherapy, exemplified
by the 5-year survival of more than 50% of patients with
►►
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stage IV melanoma treated by combination checkpoint
inhibitors. Immunotherapy was named Science magazine’s
breakthrough of the year in 2013, and Dr James Allison
and Dr Tasuku Honjo received the 2018 Nobel Prize for
their contributions to the development of checkpoint
inhibitors to treat patients with cancer. Despite this
excitement, challenges remain, with low response rates
in the majority of tumor types and the unique profile
of immune-
related adverse events (irAEs), which are
hard to manage. Due to this conundrum, the utilization
of biomarkers to prognosticate about patients’ overall
cancer outcomes (regardless of therapy) or to predict
response and toxicity from the effect of a therapeutic
intervention, especially immunotherapy, is warranted.
Both prognostic biomarkers (such as expression levels
of programmed death-
ligand 1 (PD-
L1) and PD-
L2
to predict survival outcomes in patients) and predictive biomarkers of response and toxicity are dealt with
due to this urgent need, and these biomarkers are key
to successful immunotherapy development, which is in
the midst of an explosion of innovation. As demarcated
by the National Cancer Institute (NCI) Dictionary of
Cancer Terms, a biomarker is defined as:

Ipilimumab plus dacarbazine for previously untreated
metastatic melanoma.24
Subsequently, in 2014, programmed cell death-1
(PD-1)-targeting monoclonal antibodies were approved,
beginning with pembrolizumab for advanced or unresectable melanoma based on the KEYNOTE-001, KEYNOTE002, and KEYNOTE-006 trials; and nivolumab based on
the CheckMate 037, CheckMate 067, and CheckMate 069
trials. These antibodies strengthen antitumor immunity by
releasing the ‘brakes’ that cause the immune suppression
of effector T cells in the tumor microenvironment (TME).
These antibodies have been subsequently approved in the
treatment of more than 10 malignancies, spanning from
Hodgkin lymphoma to head and neck carcinoma, with
inspiring durability of response, resulting in widespread
clinical application. A newer anti-PD-1 antibody, cemiplimab (2018), was approved for cutaneous squamous
cell carcinoma based on Study 1540.
►► Anti-programmed-death-receptor-1 treatment with
pembrolizumab in ipilimumab-
refractory advanced
melanoma: a randomised dose-comparison cohort of
a phase 1 trial.25
►► Pembrolizumab
vs ipilimumab in advanced
melanoma.26
A biological molecule (molecular marker and signa►► Pembrolizumab vs investigator-choice chemotherapy
ture molecule) found in blood, other body fluids, or
for ipilimumab refractory melanoma (KEYNOTEtissues that is a sign of a normal or abnormal process,
002): a randomised, controlled, phase 2 trial.27
or of a condition or disease. A biomarker may be used
►► Nivolumab versus chemotherapy in patients with
to see how well the body responds to a treatment for
advanced melanoma who progressed after anti-
a disease or condition.
CTLA-4 treatment (CheckMate 037): a randomised,
controlled, open-label, phase 3 trial.28
Thus, this document provides comprehensive tools
►► Nivolumab and ipilimumab versus ipilimumab in
and resources with supporting publications to summarize
untreated melanoma.29
current information, facilitate biomarker discovery and
►► Combined nivolumab and ipilimumab or monovalidation, and discuss assays in development for clinical
therapy in untreated melanoma.30
use. It encompasses topics of assay standardization and
►► Development of PD-1 and PD-L1 inhibitors as a form
harmonization, novel biomarker discovery, regulatory
of cancer immunotherapy: a comprehensive review of
agency guidelines for diagnostics, and new and emerging
registration trials and future considerations.31
technologies. An attempt has been made to include
►► PD-1 blockade with cemiplimab in advanced cutamany pertinent products, resources, and publications.
neous squamous cell carcinoma.32
However, as the field of immune biomarkers is growing
In addition, PD-L1 ICIs such as atezolizumab (2016),
very rapidly, it is impossible to provide an exhaustive list
avelumab
(2017), and durvalumab (2017) were approved
of all relevant products, resources and publications. A
by
the
FDA
based on clinical trials POPLAR and OAK
summary table of online resources is provided in the last
(both
for
non-
small cell lung cancer, NSCLC), Study 1108
section.
(refractory urothelial carcinoma), and JAVELIN (metaRecently approved cancer immunotherapies—a breakthrough
static Merkel cell carcinoma). These antibodies target
Immune checkpoint inhibitors
PD-L1 expressed by tumor cells to thwart the immunoIn 2011, the first ICI, ipilimumab, an immune cell cytosuppression exerted by the interactions of PD-1 on T cells
toxic T lymphocyte-
associated protein-4 (CTLA-4)- with PD-L1 on tumor cells.
targeting monoclonal antibody, was approved by the FDA
►► Atezolizumab versus docetaxel for patients with previto treat patients with advanced melanoma based on two
ously treated non-small-cell lung cancer (POPLAR):
pivotal phase III clinical trials. Ipilimumab functions in
a multicentre, open-
label, phase 2 randomised
the priming phase of T cell activation by inhibiting the
controlled trial.33
immune suppressive CTLA-4 checkpoint and allows anti►► Atezolizumab versus docetaxel in patients with previtumor T cells to be activated and released from lymphoid
ously treated nonsmall-
cell lung cancer (OAK):
tissue.
a phase 3, open-
label, multicentre randomized
►► Improved survival with ipilimumab in patients with
controlled trial.34
23
35
metastatic melanoma.
►► IMFINZI prescribing information.
►►
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Durvalumab after chemoradiotherapy in stage III
non-small-cell lung cancer.36
►► Avelumab, an anti-
programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib
study.37
These ICIs are associated with durable responses,
a hallmark of immunotherapy, and further increased
overall survival (OS) and progression-free survival (PFS)
compared with chemotherapies and targeted therapies in
a subset of patients. On the other hand, many patients/
tumor types do not respond to these interventions. This
leads to combinatorial approaches among these ICIs and
with other established agents such as chemotherapy, radiation, and molecularly targeted therapeutics. With the
identification of more immune checkpoint molecules
(eg, lymphocyte-activation gene 3 (LAG3), T cell immunoglobulin and mucin domain 3 (TIM3), B7-H3 (also
known as CD276), V-domain Ig suppressor of T cell activation (VISTA) and adenosine A2A receptor (A2AR)),
new options for single and combined therapy regimens
with already approved ICIs are being explored in many
ongoing clinical trials. However, irAEs can be severe, with
unpredictable patterns of occurrence. For the continued
successful development of cancer immunotherapies,
biomarkers predicting response, resistance mechanisms,
immune-
related toxicities, and hyperprogression are
paramount.
►► Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve
outcomes in melanoma.38
►►

Adoptive cell therapy
In 2017, the first anti-CD19 chimeric antigen receptor
(CAR) T cell product, tisagenlecleucel (Kymriah), was
approved for the treatment of pediatric and young adult
patients with relapsed and/or refractory B cell precursor
acute lymphoblastic leukemia, based on the ELIANA trial.
This was followed by the second anti-CD19 CAR, axicabtagene ciloleucel (Yescarta), which was approved based on
the ZUMA-1 trial for the treatment of adult patients with
relapsed or refractory large B cell lymphoma. Despite
great promise, treatment-related toxicities, relapse due to
loss of CD19 on tumor cells, and lack of specificity (eg,
targeting CD19 that is also expressed by other cells such as
follicular dendritic cells) remain important issues. Therefore, identifying patients who would benefit from the
therapy and preventing or managing unwanted toxicity,
along with additional development of CAR T cell therapeutics for successful clinical application, are warranted.
►► Tisagenlecleucel in children and young adults with
B-cell lymphoblastic leukemia.39
►► Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.40
Cancer vaccines
Provenge (sipuleucel-T) is a cancer vaccine consisting of
autologous dendritic cells loaded with a prostate tumor
4

antigen, prostatic acid phosphatase (PAP), along with
other peripheral blood mononuclear cells (PBMCs). It
was the first therapeutic cancer vaccine approved by the
FDA in 2010, based on three double-blind, randomized
phase III studies on asymptomatic/minimally symptomatic metastatic castration-
resistant prostate cancer and
finally on the IMPACT trial reported by Kantoff PW et al.41
SITC produced a clinical practice guideline on this treatment approach for prostate cancer. Again, the real challenges with Provenge, apart from production issues, are
the single-antigen targeting approach and methodological variation in detecting PAP as a biomarker to determine treatment options.
►► Placebo-
controlled phase III trial of immunologic
therapy with sipuleucel-T (APC8015) in patients with
metastatic, asymptomatic hormone refractory prostate cancer.42
►► Integrated data from 2 randomized, double-
blind,
placebo-
controlled, phase 3 trials of active cellular
immunotherapy with sipuleucel-T in advanced prostate cancer.43
►► Sipuleucel-
T immunotherapy for castration-resistant
prostate cancer.41
►► The Society for Immunotherapy of Cancer consensus
statement on immunotherapy for the treatment of
prostate carcinoma.44
Oncolytic viral immune therapy
Oncolytic viruses (OVs) embody a new class of therapeutic agents that facilitate antitumor responses by
combining selective tumor cell killing and the induction
of systemic antitumor immunity. There are three OVs
that have received regulatory approval: Rigvir in Latvia,
Georgia, and Armenia; Oncorine H101 in China; and
talimogene laherparepvec (T-VEC, Imlygic) in the USA.
These consist of an echovirus, an adenovirus, and a herpes
simplex-1 virus, respectively. Owing to the approval of
T-VEC for treatment of melanoma in 2015 by the FDA,
based on data from a pivotal phase III trial (OPTiM) in
patients with advanced melanoma, oncolytic viral therapy
has been accepted as a standard immunotherapy in the
USA. However, the benefit of single-agent T-VEC delivered intralesionally is marginal in patients with visceral
metastases. In order to enhance response rates, newer
generations of OVs such as HF10 (canerpaturev, C-REV)
and CVA21 (CAVATAK) are being tested as monotherapies and in combination with ICIs. Important hurdles for
OV therapy are the presence of pre-existing antibodies to
these viruses in vaccinated or seropositive patients, and
the intact innate responses of tumor cells or immune cells
in the TME that affect viral replication.
►► OPTIM trial: a phase III trial of an oncolytic herpes
virus encoding GM-CSF for unresectable stage III or
IV melanoma.45
►► Talimogene laherparepvec improves durable response
rate in patients with advanced melanoma.46
►► The emerging role of oncolytic virus therapy against
cancer.47
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Table 1 Recently approved immunotherapies
Drug name

Type of
agent

Target

Supporting study

Year approved

FDA-approved use on first
approval

Ipilimumab
Pembrolizumab

ICI
ICI

CTLA-4
PD-1

NCT00094653
KEYNOTE-001
(NCT01295827)

2011
2014

Melanoma
Melanoma

Nivolumab

ICI

PD-1

CheckMate 037
(NCT01721746)

2014

Melanoma

Cemiplimab

ICI

PD-1

Study 1423
(NCT02383212),
Study 1540
(NCT02760498)

2018

Cutaneous squamous cell
carcinoma

2016

Atezolizumab

ICI

PD-L1

NCT02108652

Avelumab

ICI

PD-L1

JAVELIN Merkel 200 2017
(NCT02155647)

Merkel cell carcinoma

Durvalumab

ICI

PD-L1

Study 1108
(NCT01693562)

2017

Urothelial carcinoma

Tisagenlecleucel

CAR T cell

CD19

ELIANA
(NCT02435849)

2017

B cell precursor acute
lymphoblastic leukemia

Axicabtagene
ciloleucel

CAR T cell

CD19

ZUMA-1
(NCT02348216)

2017

Large B cell lymphoma

Sipuleucel-T

Vaccine
Oncolytic
virus

IMPACT
(NCT00065442)
OPTiM
(NCT00769704)

2010

Talimogene
laherparepvec

Prostatic acid
phosphatase
Tumor cells

Castration-resistant prostate
cancer
Melanoma

2015

Urothelial carcinoma

CAR T cell, chimeric antigen receptor T cell; CTLA-4, cytotoxic T lymphocyte-associated protein-4; FDA, Food and Drug Administration; ICI,
immune checkpoint inhibitor; PD-1, programmed cell death protein-1; PD-L1, programmed death-ligand 1.

A summary of the immunotherapies discussed above
may be found in table 1.
Biomarkers of immune response and clinical outcome in
patients with cancer
As highlighted above, immunotherapy has radically transformed the standard of cancer treatment but suffers
from low frequency of benefit due to the complexity of
resistance mechanisms. In order to increase the clinical
efficacy of immunotherapy, combinations of immunotherapeutic agents and standard therapies are being
developed. In this regard, the characterization and monitoring of immune responsiveness during immunotherapy
treatment are important to understand the mechanisms
of action of these therapeutic regimens, to optimize
patient stratification and selection for combination strategies, and to monitor and predict treatment-related toxicities. Recent reviews by Pilla L and Maccali C,48 Darvin P et
al,49 Lu S et al,50 and Wang Y et al51 focus on correlation of
clinical responsiveness with different immunomonitoring
strategies such as circulating immune cells (including
absolute leukocyte count (Weide B et al,52 Martens A et
al,53 Subrahmanyam PB et al54)), TME-associated immune
cells, soluble serum markers, host microbiome, PD-L1
overexpression, neoantigens, and genetic and epigenetic signatures. A more detailed discussion on different
biomarkers is provided in the last part of this section.

►►
►►
►►

►►

►►

►►

►►

Immune profiling of cancer patients treated with
immunotherapy: advances and challenges.48
Immune checkpoint inhibitors: recent progress and
potential biomarkers.49
Comparison of biomarker modalities for predicting
response to PD-1/PD-
L1 checkpoint blockade: a
systematic review and meta-analysis.50
Modulation of gut microbiota: a novel paradigm of
enhancing the efficacy of programmed death-1 and
programmed death ligand-1 blockade therapy.51
Myeloid-derived suppressor cells predict survival of
patients with advanced melanoma: comparison with
regulatory T cells and NY-ESO-1- or melan-A-specific
T cells.52
Baseline peripheral blood biomarkers associated with
clinical outcome of advanced melanoma patients
treated with ipilimumab.53
Distinct predictive biomarker candidates for response
to anti-
CTLA-4 and anti-
PD-1 immunotherapy in
melanoma patients54

Biomarkers of immune-related adverse events and correlation
with clinical response
As highlighted above, several factors have been shown to
have potential as biomarkers for tumor response to ICIs,
but factors which can predict irAEs are less common.
IrAEs are diverse and vary according to the ICI agent.
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In this regard, a recent review by Nakamura,55 which
highlights recent advances in the understanding of
biomarkers for tumor response and the occurrence of
irAEs in patients with cancer treated with ICIs, is valuable. Although controversial, the correlation of severe
irAEs with clinical efficacy has been reported in NSCLC,
head and neck, and other cancers. In a 2019 meeting
abstract presentation, a higher rate of objective response
and lower progression and death rates were reported in
a cohort of patients with urothelial cancer who experienced irAEs. In another meeting report, the development
of irAEs was associated with clinical benefit for patients
with advanced gastric cancer receiving nivolumab monotherapy. Further studies with larger numbers of patients
and longer follow-up are needed to validate these findings, in addition to developing biomarker-based assays to
predict the development of irAEs.
►► Do immune-
related adverse events correlate with
response to immune checkpoint inhibitors?.56
►► Association between immune-
related adverse events
(irAEs) and clinical outcomes (CO) in advanced
urothelial cancer patients (pts) treated with immunotherapy (IO).57
►► Correlation between immune-
related adverse events
and prognosis in patients with gastric cancer treated
with nivolumab.58
►► Biomarkers for immune checkpoint inhibitor-
mediated tumor response and adverse events.55
Quantifying the antitumor immune response
Tumor development, or response to immunotherapy,
dynamically shapes the composition and function of the
immune response. The following select recent reviews
and original research papers explore some of the current
immunotherapies being assessed in patients with cancer
and describe the experimental tools available for monitoring their antitumor immune response prior to or
during treatment.
►► Quantifying the anti-
tumor immune response in
patients receiving immunotherapy.59
►► Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival60
►► Association between expression level of PD1 by tumor-
infiltrating CD8+ T cells and features of hepatocellular
carcinoma.61
►► The development, function, and plasticity of the
immune macroenvironment in cancer.62
►► Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation63
►► Quantifying antigen-
specific T cell responses when
using antigen-agnostic immunotherapies.64
The development and validation of immunotherapy
biomarkers
Recent comprehensive reviews by the SITC Biomarkers
Committee (Masucci GV et al3 and Dobbin KK et al4)
deal with considerations for preanalytical, analytical, and
clinical validation of biomarkers to predict responses to
6

cancer immunotherapy. Gnjatic S et al5 describe baseline
immune-related biomarkers and how those biomarkers
could predict the clinical outcome of immunotherapy.
Lastly, the challenges to developing valuable immuno-
oncology biomarkers are outlined by Mehnert JM et al.65
►► Validation of biomarkers to predict response to
immunotherapy in cancer: volume I—pre-analytical
and analytical validation.3
►► Validation of biomarkers to predict response to immunotherapy in cancer: volume II—clinical validation
and regulatory considerations.4
►► Identifying baseline immune-
related biomarkers to
predict clinical outcome of immunotherapy.5
►► The challenge for development of valuable immuno-
oncology biomarkers.65
Data harmonization efforts for biomarker discovery
CIMAC/CIDC network
In 2017, the US NCI funded the CIMAC and the CIDC,
as part of the Cancer Moonshot program. The CIMAC
constitutes four academic centers (Dana-Farber Cancer
Institute, MD Anderson Cancer Center, Mount Sinai
School of Medicine, and Stanford University Medical
School), which are responsible for providing standardized, analytically validated, state-of-the-art immune monitoring assays for early-stage NCI trials involving cancer
immunotherapy. The CIDC, housed at the Dana-Farber
Cancer Institute, will create a database for aggregation and integrated analysis of CIMAC data, biomarker
discovery, and sharing with the scientific community. For
more information, see:
66
►► https://cimac-network.org/
In partnership with the CIMAC/CIDC network, a
consortium of 11 biopharmaceutical companies was
created by the Foundation for the National Institutes of
Health. Called PACT, this public–private collaboration
will extend the CIMAC/CIDC activities to include additional non-NCI clinical trials, with the goal of accelerating
biomarker discovery in immuno-oncology. More information can be found at:
►► h t t p s : / /  f n i h .  o r g /  w h a t -  w e -  d o /  p r o g r a m s /
partnership-for-accelerating-cancer-therapies67
Assay standardization and harmonization
Standardization and harmonization are two integral parts
for controlling the performance of biomarker assays to
allow for consistency and comparability of results. Standardization of an operational assay procedure addresses
each single variable of an assay, and is hence restricted to a
specific application and laboratory or laboratory network
that follows the established standard operating procedure
(SOP) for the defined application. Standardization is a
prerequisite for assay validation. Reviews and guidelines
on biomarker assay standardization are numerous. More
information is provided within the specific assay subsections of this document.
Assay harmonization addresses the major limitations of
assay standardization, which are twofold: (1) explorative
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biomarker assays often require procedural adaptations,
and (2) countless minute assay variables exist, which
are impossible to standardize across a large number of
laboratories. Harmonization focuses on key protocol variables that influence the assay outcome, and their alignment across laboratories and SOPs. Assay harmonization
efforts are currently underway in the CIMAC network for
cytometry by time of flight (CyTOF), single parameter
and multiplex immunohistochemistry (IHC), RNA-seq,
and whole exome sequencing (WES), as these assays are
performed across multiple CIMAC centers. An outline for
achieving biomarker assay harmonization has been given.
►► Harmonization of immune biomarker assays for clinical studies.68
Sample collection: technical considerations for processing,
storage, and shipment of tumor samples for immunological
studies
Regardless of the assay type (eg, detection of DNA, RNA,
or protein expression), quality of data is largely influenced by the quality of the biospecimens used (eg, blood
including isolated serum/plasma and mononuclear
immune cells, body fluid, tissue such as tumors, and so
on). Factors influencing the quality of biospecimens are
often referred to as preanalytical variables, which involve
sample processing, storage, and shipment. A comprehensive list of guidelines on the best practices for biorepositories and biospecimens is available from the NCI, which
includes comprehensive checklists created by the College
of American Pathologists (CAP). The International
Society for Biological and Environmental Repositories
(ISBER) also publishes Best Practices for Repositories,
which reflects the collective experience of repository
professionals.
69
►► https://biospecimens.cancer.gov/bestpractices/
►► https://www. c ap.  o rg/  l aboratory-  i mprovement/
accreditation/accreditation-checklists70
71
►► https://www.isber.org/page/BPR
The following reviews discuss the most up-
to-
date
understanding of preanalytical variables:
72
►► Preanalytical challenges - time for solutions.
73
►► The root causes of pharmacodynamic assay failure
►► Tumor pre-
analytics in molecular pathology: impact
on protein expression and analysis.74
►► Understanding preanalytical variables and their
effects on clinical biomarkers of oncology and
immunotherapy.75
Reporting of biomarker data in clinical trials and publications
To allow an objective evaluation of biomarker data, the
reporting has to follow standards of conformity and transparency to support the rigor required for reproducibility
and confidence in the data. The REMARK (REporting
recommendations for tumor MARKer prognostic studies)
guidelines for prognostic tumor marker studies have
been widely accepted.76 Reporting recommendations for
specific biomarker assays exist as minimal information
guidelines, and are further addressed in this document,

for example, for microarray assays,77 T cell assays,78 and
flow cytometry assays.79 A review commentary about
achieving greater reproducibility and credibility of early
clinical biomarker studies, including data reporting, has
recently been published.80
►► REporting recommendations for tumor MARKer
prognostic studies (REMARK).76
►► Minimum information about a microarray experiment (MIAME)—toward standards for microarray
data.77
►► T cell assays and MIATA: the essential minimum for
maximum impact.78
►► MIFlowCyt: the minimum information about a flow
cytometry experiment.79
►► In pursuit of greater reproducibility and credibility of
early clinical biomarker research.80
Conclusions
For new biomarker discovery, using validated assays is
important, especially in larger clinical trials. Harmonization of assays across sites is difficult but needed whenever
multiple sites are expected to generate comparable data.
Control of preanalytical variables is key to the success of
biomarker assays, and standardized reporting is required
for effective evaluation and data reuse.
Novel biomarker discovery: immunotherapy biomarker useful
literature review
PD-L1 expression
Anti-
PD-1 checkpoint inhibitors have revolutionized
cancer care. Six PD-
(L)1-
specific antibodies including
nivolumab
(Opdivo;
anti-
PD-1),
pembrolizumab
(Keytruda; anti-
PD-1), atezolizumab (Tecentriq; anti-
PD-
L1), durvalumab (Imfinzi; anti-
PD-
L1), avelumab
(Bavencio; anti-PD-L1), and cemiplimab (Libtayo; anti-
PD-1) have been approved by the US FDA in specific
tumor indications; clinical benefit from this class of agents,
however, is restricted to a subset of patients. Assessment
of tumor PD-L1 expression by IHC was a rational choice
for biomarker development, and a number of PD-L1 IHC
assays, including 28-8 pharmDx (Agilent), 22C3 pharmDx
(Agilent), Ventana SP142 (Roche Diagnostics), Ventana
SP263 (Roche Diagnostics) and Dako/Agilent 73-10
(Agilent), have been developed to support patient selection and diagnostic strategies for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab,
respectively. However, it has become apparent that PD-L1
protein is an imprecise biomarker in predicting clinical
benefit from PD-(L)1-specific antibodies. While multiple
studies have found a positive correlation between tumor
PD-
L1 expression and clinical efficacy of anti-
PD-1
blockade, others have detected no association. Many
patients with PD-L1-negative tumors also derive durable
clinical benefit from anti-PD-1 inhibitors. The contradictory data from correlative studies around PD-L1 IHC are
attributable to multiple factors, including the inducible
nature and intertumor and intratumor heterogeneity
of PD-
L1 expression and technical variations, such as
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different detection antibodies and assay platforms used,
archival versus fresh tumor tissue, type and duration of
tissue fixation, non-standardized criteria, and various cut-
off levels to define positive expression.
►► Comparing and contrasting predictive biomarkers for
immunotherapy and targeted therapy of NSCLC.81
►► Monitoring immune-
checkpoint blockade: response
evaluation and biomarker development.82
►► Mechanism-
driven biomarkers to guide immune
checkpoint blockade in cancer therapy.83
84
►► What does PD-L1 positive or negative tumors mean?
►► Predictive biomarkers for checkpoint inhibitor-based
immunotherapy.85
►► PD-L1 expression as a predictive biomarker in cancer
immunotherapy.86
Assessment of PD-
L1 expression on tumor versus
immune cells adds another level of complexity. In certain
tumor types (eg, squamous cell carcinoma of the head
and neck (SCCHN), melanoma, breast cancer and
renal cell carcinoma (RCC)), PD-L1 is expressed on the
surface of both tumor and immune cells (macrophages,
dendritic cells, and activated T cells), whereas in others
such as colorectal cancer (CRC) and gastric carcinoma,
PD-
L1 expression is predominantly seen on tumor-
infiltrating immune cells. In certain tumor types, clinical
activity of PD-(L)1 inhibitors is associated with PD-L1 on
immune rather than tumor cells. Therefore, scoring algorithms based on PD-L1 expression in both the tumor and
immune cell compartments have been established.
►► Predictive correlates of response to the anti-
PD-
L1
antibody MPDL3280A in cancer patients.87
►► Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):
a multicentre, open-
label, phase 2 randomised
controlled trial.33
►► Atezolizumab in patients with locally advanced and
metastatic urothelial carcinoma who have progressed
following treatment with platinum-
based chemotherapy: a single-arm, multicentre, phase 2 trial.88
►► Clinical utility of the combined positive score for
programmed death ligand-1 expression and the
approval of pembrolizumab for treatment of gastric
cancer.89
►► Establishing a complementary diagnostic for anti-
PD-1 immune checkpoint inhibitor therapy.90
In contrast to complementary tests (which assist in
risk-benefit analysis but are not required for the use of a
therapy), companion diagnostic (CDx) tests are required
for use with a specific therapy to identify patients who are
most likely to benefit from that therapy. For pembrolizumab, for example, the 22C3 pharmDx assay has been
approved by the FDA as a CDx test to help identify eligible
patients with NSCLC, gastric or gastroesophageal junction (GEJ), cervical, and urothelial carcinoma. PD-
L1
expression in NSCLC is determined using the Tumor
Proportion Score (TPS), which is the percentage of
viable tumor cells showing partial or complete membrane
PD-L1 staining at any intensity. An NSCLC specimen is
8

considered PD-L1-positive for the purposes of first-line
treatment with pembrolizumab monotherapy if the
TPS is ≥ 1% of tumor cells. PD-L1 protein expression in
gastric/GEJ, cervical, SCCHN, esophageal squamous cell
carcinoma, and urothelial carcinomas is determined by
the Combined Positive Score (CPS), which is defined as
the percentage of PD-L1-positive tumor and immune cells
relative to the total number of tumor cells. The sample is
considered to have PD-L1 expression if it has a CPS ≥1
for gastric/GEJ, SCCHN, and cervical carcinomas and
≥10 for urothelial cell carcinoma (UCC) and esophageal
squamous cell carcinoma. The FDA also approved the
Ventana SP142 assay as a CDx test to select patients with
(1) locally advanced or metastatic UCC who are cisplatin-
ineligible for single-agent treatment with atezolizumab or
unresectable/locally advanced and (2) metastatic triple-
negative breast cancer (TNBC) for combination treatment with atezolizumab and nanoparticle albumin-bound
paclitaxel. The SP142 assay determines tumor PD-L1 positivity as PD-L1 stained tumor-infiltrating immune cells of
any intensity covering ≥1% or 5% of the tumor area in
TNBC and UCC, respectively.
►► https://www.fda.gov/drugs/resources-information-
approved- d rugs/ f da- g rants- a ccelerated- a pproval-
pembrolizumab-advanced-gastric-cancer91
►► https://www.fda.gov/drugs/resources-information-
approved-  d rugs/  f da-  u pdates-  p rescribing- i nformation-keytruda-and-tecentriq92
►► https://www. f da. g ov/ d rugs/ r esources-  i nformation-approved-drugs/fda-approves-pembrolizumab-
advanced-cervical-cancer-disease-progression-during-
or-after-chemotherapy93
►► https://www.fda.gov/Drugs/InformationOnDrugs/
ApprovedDrugs/ucm633065.htm94
►► https://www.fda.gov/drugs/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-195
►► https://www.fda.gov/drugs/resources-information-
approved-drugs/fda-approves-pembrolizumab-first-
line-treatment-head-and-neck-squamous-cell-carcinoma96
►► https://www. f da. g ov/ d rugs/ r esources-  i nformation-approved-drugs/fda-approves-pembrolizumab-
advanced-esophageal-squamous-cell-cancer97
Currently, there is no standardized approach for PD-L1
testing. Significant heterogeneity was reported for the
available PD-L1 IHC tests, with different cut-off points
and testing standards, which makes interpretation of the
PD-L1 expression data across various clinical trials very
challenging. In the Blueprint PD-L1 IHC Assay Comparison Project (an industrial–academic collaborative partnership), as well as in a similar National Comprehensive
Cancer Network (NCCN) project, different PD-L1 IHC
assays, including 28-8 pharmDx, 22C3 pharmDx, Ventana
SP142, Ventana SP263, and Dako/Agilent 73-10, were evaluated to provide information on their analytical and clinical comparability. The results of this effort demonstrated
comparable analytical results for the 22C3, 28-8, and
SP263 assays, but differences were noted with regard to
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the SP142 and 73-10 assays for determining TPS on tumor
cells. A greater variability between tests was observed
when PD-L1 expression was analyzed on immune cells.
Although the data suggest possible interchangeability of
some PD-L1 IHC tests (but not for assessment of PD-L1
expression on immune cells), some discordance in the
results was apparent, and the interchangeable use of
these assays may result in misclassification of PD-L1 status
for some patients. A recent meta-analysis suggests that the
FDA-approved PD-L1 IHC assays that were designed and
approved for a different purpose may not be interchangeable with each other. In contrast, well-designed, fit-for-
purpose PD-L1 laboratory-developed IHC tests appear to
achieve higher accuracy than the FDA-approved PD-L1
IHC assays when both are compared with an appropriate
designated reference standard.
►► PD-L1 immunohistochemistry assays for lung cancer:
results from phase I of the Blueprint PD-L1 IHC assay
comparison project.98
►► Programmed death ligand-1 immunohistochemistry
testing: a review of analytical assays and clinical implementation in non-small cell lung cancer.99
►► PD-L1 immunohistochemistry comparability study in
real-life clinical samples: results of Blueprint phase 2
project.100
►► A prospective, multi-
institutional, pathologist-
based
assessment of 4 immunohistochemistry assays for
PD-L1 expression in non-small cell lung cancer. 101
►► Automated image analysis of NSCLC biopsies to
predict response to anti-PD-L1 therapy.102
►► “Interchangeability” of PD-L1 immunohistochemistry
assays: a meta-analysis of diagnostic accuracy.103
Prognostic prediction of PD-L1 and PD-L2 expression
A meta-
analysis study suggests that PD-
L1 overexpression is related to poor OS in patients with cervical cancer
and poor PFS in Asian patients with cervical cancer. This
study also suggests that PD-L1 expression is a promising
prognostic indicator for cervical cancer. In this scenario,
PD-L1 assay validation is critical for its utility in routine
clinical practice.
►► Elevated PD-
L1 expression predicts poor survival
outcomes in patients with cervical cancer.104
Although PD-L2 is more confined to antigen-presenting
cells, its expression has been discovered in many tumor
types owing to induction by stimuli in the TME. A recent
meta-analysis revealed that high PD-L2 expression in solid
tumors, especially in hepatocellular carcinoma (HCC),
predicts tumor metastasis and unfavorable prognosis
after surgery. In this scenario, it is unknown what additional correlation might be achieved by combining PD-L2
with PD-L1 measurement.
►► Correlation between PD-
L2 expression and clinical
outcome in solid cancer patients: a meta-analysis.105
Conclusions
PD-L1 IHC has demonstrated clinical utility by allowing
patient selection and enrichment for clinical benefit

from single-agent treatment with anti-PD-1 checkpoint
inhibitors. A number of PD-
L1 IHC tests were independently codeveloped to support specific anti-PD-(L)1
programs, and the lack of standardization between these
IHC requires harmonization of these assays in the clinic,
as well as consensus on the scoring algorithms and cut-
off levels to define positive PD-L1 status across various
tumor types. While PD-
L1 IHC tests allow for enrichment of patients who are likely to derive clinical benefit
from anti-PD-(L)1 agents, their clinical utility is less clear
in the context of combination immunotherapies (eg,
nivolumab/ipilimumab, angio-
immunotherapy, and
chemoimmunotherapy) which, based on currently available data, appear to be efficacious irrespective of tumor
PD-L1 status.
Tumor mutational burden
Human tumors harbor a varying number of somatic
mutations collectively referred to as tumor mutational
burden (TMB). TMB has become a useful biomarker
in immuno-oncology following the demonstration that
a correlation between high TMB and clinical efficacy of
ICIs exists across multiple tumor types. Initial interest
in TMB was triggered by two exploratory studies of WES
data obtained from patients with melanoma; a correlation
between TMB and the magnitude of clinical benefit in
ipilimumab (anti-CTLA-4)-treated patients was observed.
►► Genetic basis for clinical response to CTLA-4 blockade
in melanoma.106
►► Genomic correlates of response to CTLA-4 blockade
in metastatic melanoma.107
In addition, a high response rate to anti-PD-1 checkpoint inhibitors was observed in desmoplastic melanoma,
a subtype of melanoma that has very high median mutational burden.
►► High response to PD-1 blockade in desmoplastic
melanoma.108
Similar observations were made in patients with NSCLC
treated with anti-PD-1 antibodies.
►► Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer.109
The clinical relevance of TMB was further demonstrated in a study of mismatch repair-deficient tumors
(frequently detected as tumors with high microsatellite
instability (MSI-H)); these tumors exhibited a markedly
increased mutational load and displayed high objective
response rates after anti-PD-1 blockade.
►► PD-1 blockade in tumors with mismatch repair
deficiency.110
Based on the results of larger randomized and non-
randomized clinical trials (Checkmate-012, Checkmate-569, Checkmate-227), TMB has emerged as a
potential biomarker predictive of clinical benefit in
patients with NSCLC treated with combined ICIs (in
this case, nivolumab/ipilimumab). Ten mutations per
megabase was identified as an optimal cut-off level to
define the NSCLC patient population with high TMB.
However, while high TMB appears to be associated with
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improved PFS, a correlation between TMB and OS in
patients treated with combined immune checkpoint
blockade has not been demonstrated.
►► Genomic features of response to combination immunotherapy in patients with advanced non-small cell
lung cancer.111
►► Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden.112
►► First-line nivolumab plus ipilimumab in advanced non-
small-cell lung cancer (CheckMate 568): outcomes by
programmed death ligand 1 and tumor mutational
burden as biomarkers.113
►► Nivolumab plus ipilimumab in advanced non-
small-
cell lung cancer.114
An association of TMB with response to checkpoint
blockade was also demonstrated in patients with small
cell lung cancer treated with nivolumab and ipilimumab.
►► Tumor mutational burden and efficacy of nivolumab
monotherapy and in combination with ipilimumab in
small-cell lung cancer.115
Furthermore, investigators analyzed genomic data of
>1600 patients with advanced cancer treated with some
type of ICI, whose tumors were subjected to the targeted
next-generation sequencing (NGS) test Memorial Sloan
Kettering-
Integrated Mutation Profiling of Actionable
Cancer Targets (MSK-IMPACT) established at Memorial
Sloan Kettering Cancer Center. For most, but not all,
tumor types, higher somatic TMB (highest 20% in each
histology) correlated with improved survival in patients
receiving ICIs across multiple cancer types; however,
based on these data one universal definition of high TMB
appears to be unlikely.
►► Tumor mutational load predicts survival after immunotherapy across multiple cancer types.116
In line with these data, another study of whole exomes
of microsatellite stable tumors (n=294) concluded that
TMB has insufficient predictive power to differentiate
tumor responses from progressive disease, and therefore
additional molecular correlates should be taken into
consideration.
►► Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.117
Based on the results of the KEYNOTE clinical trials
spanning 22 tumor types and >300 patients treated with
pembrolizumab, investigators from Merck & Co also
concluded that the TMB and T cell-inflamed gene expression profiles (GEPs) exhibited only modest correlation
and were independently predictive of clinical outcome
(see ‘Immune gene expression signatures’ section for an
examination of T cell-inflamed GEPs). However, when
analyzed jointly, TMB and GEP were capable of defining
a patient population (TMB-
high/GEP-
high) deriving
maximum clinical benefit from pembrolizumab.
►► Pan-tumor genomic biomarkers for PD-1 checkpoint
blockade-based immunotherapy.118
Not all somatic mutations are alike in their potential
to generate neoantigens. Frameshift insertion and deletion (indel) mutations are believed to be a rich source
10

of immunogenic neoantigens. Indel burden may help
explain some discrepancy in the data for TMB and ICI
response in specific tumor indications, including RCC,
which has a good rate of response to ICIs (~25%),
although most patients with RCC have low TMB. RCC
had the highest frequency of indel mutations among 19
cancer types analyzed, and frameshift indel mutations
were found to be ~3 times more immunogenic than non-
synonymous mutations; the relationship between indel
burden and clinical efficacy of ICIs needs to be investigated further.
►► Insertion-and-deletion-derived
tumour-specific
neoantigens and the immunogenic phenotype: a pan-
cancer analysis.119
►► Tumor exome analysis reveals neoantigen-
specific
T-
cell reactivity in an ipilimumab-
responsive
melanoma.120
►► Checkpoint blockade cancer immunotherapy targets
tumour-specific mutant antigens.121
►► Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer.109
Somatic copy number alterations, such as amplifications and deletions, represent another complexity of
tumor-specific genomic aberrations that may affect the
tumor immune microenvironment and clinical efficacy
of ICIs.
►► Molecular and genetic properties of tumors associated with local immune cytolytic activity.122
►► Integrated molecular analysis of tumor biopsies on
sequential CTLA-4 and PD-1 blockade reveals markers
of response and resistance.123
WES of matched tumor and normal tissue samples is
a gold standard of TMB analysis. However, it requires
high coverage sequencing of ~50 Mb of genomic content
and is technically and is operationally challenging for
routine use in clinical practice. Targeted NGS panels
that use hybridization-capture methodologies such as the
FoundationOne CDx (F1CDx by Foundation Medicine)
and MSK-IMPACT assays that target 324 and 468 cancer-
related genes, respectively, have been used to assess TMB
in tumor biopsy samples; compared with WES, they have
a shorter turnaround time and are more cost-effective for
clinical sample analysis.
►► https://www. f oundationmedicine. c om/ g enomic-
testing/foundation-one-cdx124
125
►► https://www.mskcc.org/msk-impact
►► Comprehensive cancer-
gene panels can be used to
estimate mutational load and predict clinical benefit
to PD-1 blockade in clinical practice.126
►► Tumor mutational load predicts survival after immunotherapy across multiple cancer types.116
TMB quantifies the mutations found in a tumor.
Currently, there are no standards for calculating and
reporting TMB. Similar to efforts with harmonizing
PD-
L1 assays by IHC, the harmonized measurement
of TMB is ongoing, with the goal of helping reduce
potential variability and optimizing its use. The TMB
Harmonization Working Group has issued its plan for
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upcoming analyses of human tumor cells. The working
group will create a universal reference standard using
WES and identify sources of potential variability. To date,
the working group has reviewed publicly available data
from The Cancer Genome Atlas (TCGA) and identified
sources of variability between TMB calculated using WES
and various targeted panels used in the clinic. The work
is ongoing, and phase I results will be reported at an
upcoming meeting.
►► Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.127
Friends of Cancer Research TMB Harmonization Working Group
https://www.focr.org/TMB128
►► https://www.focr.org/news/friends-cancer-research-
announces-  l aunch- p hase- i i- t mb- h armonization-
project129
With the advent of methods enabling analysis of tumor-
derived DNA in the circulation (ctDNA), an approach
commonly referred to as liquid biopsy, it may be possible
to assess TMB by ctDNA sequencing. Analysis of ctDNA
using the Guardant Health NGS panel targeting 54–70
genes revealed that the total number of mutations
detected in ctDNA positively correlated with clinical
benefit from ICIs in a clinical trial of 69 patients representing 23 different cancer types. An obvious question
is whether TMB in ctDNA could accurately reflect TMB
evaluated in tumor biopsy samples. A blood-based platform using the aforementioned FoundationOne CDx
assay was capable of measuring TMB in plasma samples
(blood TMB, or bTMB) in two large randomized clinical trials (POPLAR and OAK); bTMB correlated with
TMB measured in tumor biopsy samples in NSCLC,
and therefore has the potential to identify patients who
derive clinical benefit from anti-PD-L1 treatment (such
as atezolizumab). Furthermore, preliminary results from
the MYSTIC phase III trial of first-line durvalumab with or
without tremelimumab (anti-CTLA-4) versus platinum-
based chemotherapy in NSCLC indicate that in patients
with high bTMB (≥20 mut/Mb), identified by the GuardantOMNI platform, treatment with durvalumab and
tremelimumab was associated with both OS and PFS
benefit.
►► Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-
based
immunotherapy.130
►► Blood-based tumor mutational burden as a predictor
small-
cell lung cancer
of clinical benefit in non-
patients treated with atezolizumab.131
►► Clinical potential of circulating tumour DNA in
patients receiving anticancer immunotherapy.132
►► Tumor mutational burden (TMB) as a biomarker
of survival in metastatic non-small cell lung cancer
(mNSCLC): blood and tissue TMB analysis from
MYSTIC, a phase III study of first-line durvalumab ±
tremelimumab vs chemotherapy.133
While emerging data for TMB as a biomarker predictive of efficacy of ICIs look encouraging, it is apparent
►►

that TMB assessment needs to be standardized across
platforms and laboratories. Several key factors should
be taken into consideration to enable the comparison of
TMB data across various platforms: depth and length of
sequencing reads; choice of aligners, variant callers, and
filters used; and preanalytical variability due to inconsistency in sample collection and processing, input material
quality and quantity, fixation methodology, and library
preparation should also be addressed.
►► Tumor mutational burden standardization initiatives:
recommendations for consistent tumor mutational
burden assessment in clinical samples to guide immunotherapy treatment decisions.134
►► Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.127
Defective mismatch repair
In an interesting study with a single tumor type, the
presence of a defective mismatch repair system and the
presence of tumor-infiltrating lymphocytes (TILs) could
be linked to better outcomes from novel immune-based
therapies in patients with advanced gastric cancer.
►► Mismatch repair deficiency may affect clinical
outcome through immune response activation in
metastatic gastric cancer patients receiving first-line
chemotherapy.135
►► PD-1 blockade in tumors with mismatch-
repair
deficiency.110
Using a database of more than 10000 tumors, immunogenomic analysis of data compiled by TCGA could
serve as a resource to identify patients likely to respond to
particular immunotherapies.
136
►► The immune landscape of cancer.
Conclusions
TMB and other genetic determinants have demonstrated
the potential to make immune checkpoint therapy more
precise. Clinical data in support of the predictive value of
TMB in the context of ICIs are encouraging but not fully
conclusive, and challenges remain. It remains to be seen
if tumor and/or bTMB can help identify patients who
are likely to benefit from combination immunotherapies,
including, but not limited to, angio-immunotherapy and
chemoimmunotherapy combinations. Additionally, the
variability in the current methods of TMB assessment may
complicate therapeutic decisions in the clinic. This highlights the need for standardization and harmonization of
TMB analysis and reporting across assays and laboratories.
Tumor-infiltrating T cells
T cells are the most important effector cells in the antitumor immune response. There is compelling evidence
on the prognostic significance of intratumoral CD8+ T cell
density across multiple tumor types. The location, density,
and phenotype of tumor-
infiltrating immune cells are
three important parameters of the intratumoral immune
contexture. The concept of Immunoscore was developed
by quantifying and qualifying the T cell infiltrate in the
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tumor core as well as at the invasive tumor margins to
predict tumor recurrence and survival in patients with
stage I–III colon cancer, using a four-point scale. The
potential utility of this scoring approach in other tumor
types (eg, melanoma, NSCLC) is being evaluated:
►► The immune contexture in human tumours: impact
on clinical outcome.137
►► International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.138
►► Immunoscore and immunoprofiling in cancer: an
update from the melanoma and immunotherapy
bridge.139
►► Assessing PDL-1 and PD-1 in non-
small cell lung
cancer: a novel Immunoscore approach.140
Since the antitumor activity of anti-CTLA-4 and anti-
PD-1 inhibitors is attributed at least in part to the reinvigoration of dysfunctional T cells in the TME, both the
density and location of intratumoral T cells have also
emerged as potential predictive biomarkers for ICIs.
While baseline density does not appear to correlate with
clinical activity of ipilimumab, pre-existing CD8+ (but not
CD4+) T cell infiltration at the invasive tumor margin
and within the tumor core is associated with response
to anti-PD-1 therapy in patients with melanoma. In both
anti-CTLA-4-treated and anti-PD-1-treated patients with
melanoma, increases in intratumoral T cells while on
treatment were associated with clinical activity, while a
higher proximity of CD68+ myeloid cells to CD8+ T cells
was documented in non-responders to anti-PD-1. Three
main phenotypes were described in the context of anti-
PD-1 pathway blockade: (1) the immune-desert phenotype (absence of immune cells within or around the
tumor), (2) the immune-excluded phenotype (immune
cells surrounding but not penetrating the tumor), and
(3) the inflamed phenotype (immune cells penetrating
the tumor, but presumably non-functional).
►► A prospective phase II trial exploring the association between tumor microenvironment biomarkers
and clinical activity of ipilimumab in advanced
melanoma.141
►► PD-1 blockade induces responses by inhibiting adaptive immune resistance.142
►► Analysis of immune signatures in longitudinal tumor
samples yields insight into biomarkers of response
and mechanisms of resistance to immune checkpoint
blockade.143
►► Predictive correlates of response to the anti-
PD-
L1
antibody MPDL3280A in cancer patients.87
►► Elements of cancer immunity and the cancer-immune
set point.144
In-depth immunophenotypic analyses of TILs or the
TME have shown correlation of the following T cell
phenotypes with clinical benefit from checkpoint inhibitors or cellular therapy in patients with melanoma or
NSCLC: (1) baseline frequency of tumor-infiltrating CD8+
T cells coexpressing PD-1 and CTLA-4 (PD-1hi CTLA-4hi
cells) and exhibiting an exhausted phenotype; (2) high
12

absolute levels of PD-1 on CD8+ TILs; (3) a ‘dormant’
TIL phenotype (CD3hi GzmBlo Ki67lo); (4) increased
cytolytic activity (cytolytic score defined as the geometric
mean of Perforin 1 and Granzyme A mRNA expression);
(5) reduction of non-conventional CD4+ Foxp3− PD-1+
T cells (4PD-1hi cells) on anti-PD-1 treatment; (6) ratio
of memory-like TCF7+ (also known as TCF1) to CD39+
TIM3+ cells within CD8+ T cells; (7) high frequency
of TCF1+ PD-1+ CD8+ T cells; (8) improved metabolic
fitness and low mitochondrial membrane potential of
TCF1+ stem cell memory T cells (Tscm cells); and (9)
high frequency of tissue-resident memory T cells (Trm
cells) that express the integrin CD103. The CD8+ T cells
expanded in treated tumors displayed an exhausted,
terminally differentiated phenotype, while the corresponding CD4+ T cell population displayed a T helper
1 (Th1)-like effector phenotype. There is an increased
frequency of Th1-
like T cells in melanoma samples
treated by anti-CTLA-4 compared with those treated by
anti-PD-1 antibodies.
►► Tumor immune profiling predicts response to anti-
PD-1 therapy in human melanoma.145
+
►► A transcriptionally and functionally distinct PD-1
+
CD8 T cell pool with predictive potential in non-
small-cell lung cancer treated with PD-1 blockade.146
►► A dormant TIL phenotype defines non-
small cell
lung carcinomas sensitive to immune checkpoint
blockers.147
►► Tumor and microenvironment evolution during
immunotherapy with nivolumab.148
►► Non-
conventional inhibitory CD4+Foxp3-PD-1hi T
cells as a biomarker of immune checkpoint blockade
activity.149
►► Defining T cell states associated with response to
checkpoint immunotherapy in melanoma.150
►► Checkpoint
blockade immunotherapy induces
dynamic changes in PD-1-CD8+ tumor-infiltrating T
cells.151
+
►► Subsets of exhausted CD8 T cells differentially
mediate tumor control and respond to checkpoint
blockade.152
+
+
+
►► Intratumoral Tcf1 PD-1 CD8 T cells with stem-
like
properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy.153
►► Mitochondrial membrane potential identifies cells
with enhanced stemness for cellular therapy.154
►► Single-
cell profiling of breast cancer T cells reveals
a tissue-
resident memory subset associated with
improved prognosis.155
►► Tissue-
resident memory features are linked to the
magnitude of cytotoxic T cell responses in human
lung cancer.156
►► Tissue-resident memory T cells at the center of immunity to solid tumors.157
►► Resident memory T cells, critical components in
tumor immunology.158
►► Distinct cellular mechanisms underlie anti-
CTLA-4
and anti-PD-1 checkpoint blockade.159
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Emerging data from a recent work that used T cell
receptor (TCR) sequencing coupled with functional
studies of tumor-
infiltrating T cells suggest that many
tumor-infiltrating T cells are not reactive against tumor
cells, and are in fact specific for epitopes related to viruses
(Epstein-
Barr virus (EBV), cytomegalovirus (CMV),
or influenza virus) rather than tumor antigens. These
bystander CD8+ T cells may exhibit phenotypes that
overlap with tumor-specific cells, but lack CD39 expresinfiltrating CD103+ CD39+
sion. Furthermore, tumor-
+
CD8 T cells that display an exhausted Trm phenotype
showed an enrichment for tumor-
specific cells with a
distinct tumor-specific TCR repertoire; contrary to what
their exhausted phenotype might suggest, they efficiently
kill autologous tumor cells in a major histocompatibility
complex (MHC) class I-
dependent manner, and their
frequencies positively correlate with OS in patients with
SCCHN.
►► Low and variable tumor reactivity of the intratumoral
TCR repertoire in human cancers.160
+
►► Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates.161
►► Co-expression of CD39 and CD103 identifies tumor
reactive CD8 T cells in human solid tumors.162
In two types of patients with cancer, melanoma and
NSCLC, those whose tumors exhibited increased inflammatory gene transcripts with high circulating CD4+ and
CD8+ central memory T cell (Tcm) to effector T cell
ratios had longer PFS.
►► Circulating T cell subpopulations correlate with
immune responses at the tumor site and clinical
response to PD1 inhibition in non-
small cell lung
cancer.163
Conclusions
Assessments of T cell density, location, and phenotype
in baseline and on-
treatment tumor samples provide
important insights into the role of these cells in patients
with cancer and immune checkpoint therapy. It is
apparent that complex immune monitoring approaches
and robust computational solutions are needed to better
characterize the tumor immune contexture.
Immune gene expression signatures
High-throughput gene expression profiling has enabled
the development of transcriptomic profiles in predicting
response or resistance to ICIs. Numerous gene expression
signatures have been evaluated for specific tumor types or
across multiple indications; however, their clinical utility
needs to be further explored.
A pan-cancer 18-gene T cell-inflamed signature associated with clinical benefit of pembrolizumab was developed by Merck using GEPs of baseline tumor samples
spanning nine tumor types and 220 patients. This gene
signature is predominantly represented by interferon
(IFN)-γ-responsive genes related to antigen presentation,
chemokine expression, cytolytic activity, and adaptive
immune resistance, and has been deployed in ongoing

clinical trials of pembrolizumab. An eight-
gene T-
effector/IFN-γ (Teff/IFN-γ) gene expression signature
defined by CD8A, GZMA, GZMB, IFN-γ, EOMES, CXCL9,
CXCL10, and TBX21 was developed by Genentech. This
signature was indicative of pre-existing tumor immunity
and was associated with clinical benefit from atezolizumab
in a second-line treatment of NSCLC. In line with these
data, investigators from MedImmune (now AstraZeneca)
identified a four-gene IFN-γ+ signature comprising IFN-γ,
CD274, LAG3, and CXCL9, which was associated with
clinical efficacy of durvalumab in NSCLC and UCC.
►► IFN-γ-related mRNA profile predicts clinical response
to PD-1 blockade.164
►► Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):
a multicentre, open-
label, phase 2 randomised
controlled trial.33
►► Interferon gamma messenger RNA signature in tumor
biopsies predicts outcomes in patients with non-small
cell lung carcinoma or urothelial cancer treated with
durvalumab.165
A transcriptional signature related to innate anti-
PD-1 resistance (IPRES) was identified in patients with
melanoma. The IPRES signature is driven by increased
expression of genes involved in the regulation of mesenchymal transition, cell adhesion, extracellular matrix
remodeling, angiogenesis, and wound healing, and these
transcriptomic changes are also seen in patients with
melanoma after treatment with mitogen-activated protein
kinase (MAPK) pathway inhibitors, suggesting overlapping mechanisms of resistance to MAPK and anti-PD-1
inhibitors. High scores of a pan-fibroblast transforming
growth factor-β (TGF-β) response signature were associated with lack of clinical benefit from atezolizumab
in UCC with a T cell-
excluded phenotype. Another
epithelial-
mesenchymal transition (EMT)-
related gene
expression signature helped define outcomes of patients
with UCC with high intratumoral T cell density treated
by nivolumab. In addition, the clinical efficacy of atezolizumab in metastatic RCC is inversely correlated with a
high myeloid inflammation signature defined by upregulation of interleukin (IL)-6, CXCL1, CXCL2, CXCL3,
CXCL8, and PTGS2 identified within Teffhi tumors, while
a combination of atezolizumab and bevacizumab (anti-
vascular endothelial growth factor) appeared to be efficacious in this patient population (Teffhi Myeloidhi).
►► Genomic and transcriptomic features of response to
anti-PD-1 therapy in metastatic melanoma.166
►► TGFβ attenuates tumour response to PD-L1 blockade
by contributing to exclusion of T cells.167
►► EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.168
►► Clinical activity and molecular correlates of response
to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.169
Immunophenoscore was developed using data from
TCGA for 20 tumor types based on the expression of genes
related to MHC molecules, costimulatory/coinhibitory
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molecules, effector T cells, and immunosuppressive cell
subsets, and was associated with survival in 12 tumor types
and predicted response to checkpoint inhibitors in two
independent cohorts.
►► Pan-cancer immunogenomic analyses reveal genotype-
immunophenotype relationships and predictors of
response to checkpoint blockade.170
A computational tumor immune dysfunction and
exclusion (TIDE) framework was developed using
publicly available data from >33,000 human tumor
samples with transcriptome and patient survival information by testing the effects of interactions among the
candidate genes with either cytotoxic T cells or immunosuppressive cell signatures on the risk of death.
TIDE provides signatures of both T cell dysfunction
in immunologically hot tumors and T cell exclusion in
cold tumors. When applied to pretreatment transcriptomic data from patients with melanoma subsequently
treated with ICIs, TIDE outperformed other predictive
biomarkers tested, including PD-L1 expression, TMB,
and IFN-γ signature.
►► Signatures of T cell dysfunction and exclusion predict
cancer immunotherapy response.171
Another predictive score, IMPRES (immunopredictive
score), was developed from gene expression changes of
15 rational pairwise relationships between immunoinhibitory and immunostimulatory genes associated with spontaneous immune-mediated regression of neuroblastoma
and extrapolated to other tumor types (eg, melanoma).
High IMPRES scores were found to define immunologically hot tumors and predict clinical outcomes in patients
with melanoma treated with different ICIs.
►► Robust prediction of response to immune checkpoint
blockade therapy in metastatic melanoma.172
Single-
cell RNA sequencing (scRNA-
seq) profiling
identified a transcriptional resistance program in malignant cells that is associated with T cell exclusion and
immune evasion. This cyclin-
dependent kinase 4/6
(CDK4/6)-
dependent signature was detected prior to
immunotherapy and predicted clinical responses to anti-
PD-1 therapy in an independent cohort of 112 patients
with melanoma.
►► A cancer cell program promotes T cell exclusion and
resistance to checkpoint blockade.173
Endogenous retroviral elements (ERVs), integrated
into human DNA over the past 100 million years of
primate evolution, constitute ~8.5% of the human
genome and are normally transcriptionally silent; transcription of ERV sequences can result in the activation of
RNA sensing pathways and subsequent production of type
I and/or II interferons (IFNs). There is also evidence of
tumor-specific human ERV (hERV) epitopes that can be
translated and presented on MHC class I molecules to the
cognate tumor-reactive T cell clones. A transcriptomic
hERV signature has shown prognostic value in patients
with RCC.
►► Molecular and genetic properties of tumors associated with local immune cytolytic activity.122
14

Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.174
►► ERVmap analysis reveals genome-
wide transcription
of human endogenous retroviruses.175
Furthermore, gene expression profiling of both tumor
samples and peripheral T cells enabled identification of
shared and non-overlapping transcriptomic changes in
patients treated with anti-PD-1 and anti-CTLA-4 inhibitors.
►► Analysis of immune signatures in longitudinal tumor
samples yields insight into biomarkers of response
and mechanisms of resistance to immune checkpoint
blockade.143
►► Combination therapy with anti-CTLA-4 and anti-PD-1
leads to distinct immunologic changes in vivo.176

►►

Useful reviews
Mechanism-
driven biomarkers to guide immune
checkpoint blockade in cancer therapy.83
►► Implementing TMB measurement in clinical practice:
considerations on assay requirements.177
►►

Guidelines and meeting reports
Method validation and measurement of biomarkers
in nonclinical and clinical samples in drug development: a conference report.178

►►

Regulatory agency guidelines for diagnostics
The FDA has approved two types of CDx tests for some
immuno-
oncology therapeutics and indications: PD-
L1
IHC assays and MSI analyses. There are FDA-approved
tests reporting metrics of TMB and B2M/JAK/LKB1
mutations. Regulatory agency approval and guidance on
the use of these tests may differ. Key agencies to monitor
include FDA (USA), European Medicines Agency (EMA;
European Union), Pharmaceuticals and Medical Devices
Agency (PMDA; Japan), and National Medical Products
Administration (NMPA; China). Importantly, the guidelines may change and should be monitored for the latest
updates.
The FDA issued a draft guidance document to address
the potential challenges when multiple CDx tests are
in use for the same disease indication. For instance, an
additional biopsy and/or a different CDx needs to be
obtained to have additional treatment options, which is
not optimal. With the draft guidance (references below),
manufacturers may expand current CDx tests by submitting a premarket approval, supplement, or a new ‘510(k)
application, as appropriate, to expand the labeling to
broaden the indication for use with a specific group or
class of oncology products in the same disease’.
Agencies post their guidance documents, roadmaps,
and/or approved medical devices on their websites.
USA: FDA
Example list of cleared or approved CDx devices from the
FDA:
►► https://www.fda.gov/medicaldevices/productsandm
edic  a lpr  o cedures/  i nvitrodiagnostics/  u cm301431.
htm179

Hu-Lieskovan S, et al. J Immunother Cancer 2020;8:e000705. doi:10.1136/jitc-2020-000705

Open access
FDA guidance issued April 2020:
https://www.fda.gov/regulatory-information/search-
fda-guidance-documents/developing-and-labeling-
vitro-companion-diagnostic180
►► https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm627745.htm181
►►

Europe: EMA
EMA presentations on new guidance, October 2018:
►► https://www.ema.europa.eu/documents/presentation/ p resentation- i nterface- b etween- m edicinal-
product-medical-devices-development-update-ema_
en.pdf182
EMA Competent Authorities for Medical Devices
Implementation Taskforce Roadmap 2017:
►► https://www.camd-europe.eu/wp-content/uploads/
2018/05/NEWS_171107_MDR-IVDR_RoadMap_v1.
3-1.pdf183
EMA concept paper on evolving landscape for
biomarkers and CDx (August 2017):
►► h t t p s : / / w w w.  e m a .  e u r o p a .  e u /  d o c u m e n t s /
scientific- g uideline/  c oncept-  p aper-  p redictive-
biomarker-  b ased-  a ssay-  d evelopment-  c ontext-  d rug-
development-lifecycle_en.pdf184
Japan: PMDA
Website of approvals:
►► https://www.  p mda. g o. j p/ e nglish/ r eview- s ervices/
reviews/approved-information/drugs/0002.html185
Other consortia, collaboration projects, and meeting groups
Immunoscore task force.186
PACT: a public–private partnership to aid standardization of immune therapy biomarkers.
►► Parker Institute for Cancer Immunotherapy’s ‘TESLA’
(Tumor NeoantigEN SeLection Alliance) collaborative project: neoantigen selection and the TESLA
consortium.187
►► CIDC and CIMAC/CIDC network.
►► American Association for Cancer Research Project
GENIE (Genomics Evidence Neoplasia Information
Exchange).188
►►
►►

Conclusions
The gene expression data sets generated in clinical trials
of ICIs provide important insights into the mechanisms
underlying the antitumor effects of this class of agents,
and allow for both qualitative and quantitative assessment
of the tumor immune microenvironment at baseline and
on treatment with immunomodulatory agents. Transcriptomic profiling represents a powerful and promising
approach to predict sensitivity and resistance to ICIs
and identify new targets in immuno-
oncology. While
numerous lines of evidence demonstrate the potential
of gene expression signatures to enrich for patients who
are likely to benefit from single-agent treatment with ICIs,
transcriptomic profiling may also help identify patient
populations for combination immunotherapies, as exemplified by the aforementioned data for the myeloid gene

expression signature and clinical activity of atezolizumab
+ bevacizumab versus atezolizumab in RCC. Additional
transcriptomic data are needed to help differentiate
patients with cancer who would be appropriate candidates for anti-PD-(L)1 monotherapy and for combination
immunotherapies.

New and emerging technologies for biomarker
discovery
Biomarker discovery for immunotherapy is challenging,
as the efficacy of the treatment relies not only on the characteristics of the tumor cells, but also the host’s immune
system, as well as the interaction of the immune system
and the tumor cells in the dynamic TME. In addition,
each patient may have a unique combination of features
that determine their sensitivity to a particular treatment.
Therefore, biomarker research for immunotherapy
needs to go beyond the tumor itself and explore the
TME and the host. In this section, we introduce different
technology platforms that can be useful in biomarker
discovery. For tumor immunogenicity, intrinsic resistance
and neoantigen-focused research and nucleic acid-based
platforms, including genomic, transcriptomic, epigenetic,
and PCR/hybridization techniques, are instrumental. For
dynamic changes in the tumor immune contexture and
the host’s immune susceptibility, proteomic platforms
ranging from ELISA to mass cytometry, along with multiplex imaging technologies, can be helpful. Overall, the
development of reliable biomarkers that can predict the
efficacy of different immunotherapeutic agents and their
combination is key to the success of extending the benefit
of immunotherapy to a majority of patients with cancer.
Genomic biomarker discovery
Whole exome sequencing
The protein-coding sequences of a gene are called exons,
and all the combined exons in a genome are referred
to as the exome. With existing technology, 95% of the
human exome can be sequenced. Therefore, the term
‘exome sequencing’ is more accurate than the term
‘whole-exome sequencing (WES)’. It is noteworthy that
while the human exome comprises all coding nuclear
DNA sequences, mitochondrial DNA is not included. The
exome represents less than 2% of the human genome,
but contains about 85% of known disease-related variants, establishing exome sequencing as a cost-effective
alternative to whole genome sequencing (WGS). Exome
sequencing using exome enrichment can efficiently
identify coding variants across a wide range of applications, including population genetics, genetic disease,
and cancer studies. However, exome sequencing techniques have non-standardized, highly variable coverage,
including regions of the exome that are refractory to
being accurately sequenced, such as genes containing a
pseudogene, highly repetitive coding regions, large deletions, and duplications. Therefore, it is likely that some
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clinically significant mutations would be missed by exome
sequencing due to inefficient capture of relevant exons:
►► Targeted capture and massively parallel sequencing of
12 human exomes.189
►► Educational materials—genetic testing: current
approaches.190
Cancer is driven by genomic events, and different sets of
genetic aberrations can characterize individual cancers.
The use of high-
throughput sequencing, including
exome sequencing, to identify those changes can guide
the identification of effective therapies currently available
or still in clinical trials.
►► Personalized oncology through integrative high-
throughput sequencing: a pilot study.191
►► Whole-
exome sequencing of metastatic cancer and
biomarkers of treatment response.192
Clinical implementation of genomic data to inform
therapy necessitates that clinicians interpret the patient’s
genomic profile, including both tumor and germline
DNA. Currently, only a limited number of genomic
markers in specific cancer settings have shown strong
evidence of differential response to specific therapies, as
these are targetable mutations with approved or investigational therapies. For many other known genomic alterations, there are no data or insufficient data to support
routine clinical implementation of biomarker-
based
therapy.
►► A decision support framework for genomically
informed investigational cancer therapy.193
►► Precision oncology in the age of integrative
genomics.194
Conclusions
The rapid advances in availability and affordability of
NGS technology provide the potential to include WES
in routine, genomically informed, personalized cancer
therapy. WES is a rational option because most known
driver mutations occur in exons, and thus WES is thought
to be an efficient method to identify a broad array of
possible targetable mutations. However, WES could miss
mutations outside the exons that lead to aberrant gene
activity and protein production. Development of broadly
accessible, comprehensive, and regularly updated databases that link observed genomic changes to clinically
actionable phenotypes, and continued education of clinicians and patients about advantages and limitations, will
greatly facilitate broader clinical implementation of this
approach.
TCR sequencing and clonality
Human T cells mature in the thymus from hematopoietic
progenitors, gain the ability to recognize foreign antigens,
and provide protection against a vast array of pathogens.
A complex molecular mechanism in T cells based
on somatic recombination leads to the expression of
highly polymorphic surface receptors, the TCRs, and
provides the immune system with functional plasticity.
TCR sequencing (TCR-seq) produces large numbers of
16

short DNA sequences covering key regions of the TCR
coding sequence, allowing quantification of T cell diversity at high resolution. Reduced cost of high-throughput
sequencing technologies has enabled the identification
of immune response signatures based on sequence analysis. In consequence, high-throughput TCR-seq has been
established as a tool to analyze antigen specificity, clonality, and diversity of T lymphocytes:
►► Linking T-cell receptor sequence to functional phenotype at the single-cell level.195
►► Overview of methodologies for T-cell receptor repertoire analysis.196
The characterization of the TCR repertoire through
TCR-seq is of great scientific and potential clinical relevance because it accurately describes T cell dynamics in a
wide range of diseases, including infection, autoimmune
diseases, and malignancies:
►► Tumor-
infiltrating lymphocytes in colorectal tumors
display a diversity of T cell receptor sequences that
differ from the T cells in adjacent mucosal tissue.197
►► TCR sequencing facilitates diagnosis and identifies
mature T cells as the cell of origin in CTCL.198
►► Characteristics of tumor infiltrating lymphocyte and
circulating lymphocyte repertoires in pancreatic
cancer by the sequencing of T cell receptors.199
►► A new high-throughput sequencing method for determining diversity and similarity of T cell receptor
(TCR) α and β repertoires and identifying potential
new invariant TCR α chains.200
High-
throughput TCR-
seq is rapidly evolving, and
numerous validated procedures for clonotype identification and TCR repertoire analysis exist. However, no
gold standard method has been established in the field.
A number of platforms are available, including DNA-
based (eg, Adaptive), RNA-
based (eg, iRepertoire),
bulk TCR-seq, and single-cell TCR-seq (10X) technologies. Different approaches may be more applicable than
others for different scientific purposes, but can be subject
to possible method-specific biases. There are innovative
approaches, such as combining TCR-seq with an assay for
accessible chromatin analysis at the single
transposase-
cell level for information on TCR specificity and the epigenomic state of individual T cells, which will likely expand
the academic and clinical utility of this technology:
►► Single cell T cell receptor sequencing: techniques and
future challenges.201
►► Transcript-
indexed ATAC-seq for precision immune
profiling.202
►► Quantifiable predictive features define epitope-
specific T cell receptor repertoires.203
►► Identifying specificity groups in the T cell receptor
repertoire.204
►► Using T cell receptor repertoires to understand the
principles of adaptive immune recognition.205
Conclusions
TCR-seq, clonality, and repertoire analysis are valuable
tools to help elucidate T cell biology in healthy individuals
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and pathological conditions, including cancer. It is being
used not only to investigate mechanisms of immune-
mediated diseases, but also to monitor immune responses
to therapies, including immunotherapy. Sequencing the
TCRs of thousands of cells in parallel is a powerful technology to dissect the complexity and diversity of the T
cell response repertoire. Advances in single-cell technologies and corresponding data management can deliver
accurate sequence information on paired alpha and beta
chains of individual cells, and enable high-throughput
TCR-seq as a routine tool for immune monitoring and
biomarker development.
Epigenetic immune cell quantification with qPCR-based assisted
cell counting (qPACC)
DNA-
based, immune cell subset-
specific epigenetic
markers have recently been identified and can be used to
differentiate leukocytes, lymphocytes, and other cell types
of interest. These markers can also be used for epigenetic
cell counting.
►► DNA demethylation in the human FOXP3 locus
discriminates regulatory T cells from activated
FOXP3+ conventional T cells.206
►► Quantitative DNA methylation analysis of FOXP3 as a
new method for counting regulatory T cells in peripheral blood and solid tissue.207
►► Epigenetic
quantification of tumor-
infiltrating
T-lymphocytes.208
Relative cell numbers can be quantified using quantitative real-
time PCR (qPCR) based on knowledge of
unmethylated DNA regions of previously characterized cell types, in combination with bisulfite conversion
(BSC). During BSC, unmethylated cytosines in DNA
convert to uracil, but methylated cytosines are protected
and remain unchanged. The resulting sequence changes
are the foundation for developing differentiating primer
and probe sets for qPCR on clinical samples. Different
cell types relevant for immune monitoring during immunotherapy have been described, for example, Treg,
CD3+, CD4+, and CD8+ T cells, B cells, natural killer (NK)
cells, and neutrophils. In addition, several approaches
to control, calibration, and quantification are used that
allow the calculation of immune cell concentrations with
qPCR-based assisted cell counting (qPACC), in a process
referred to as epigenetic cell counting.
►► Quantitative real-
time PCR assisted cell counting
(qPACC) for epigenetic-based immune cell quantification in blood and tissue.15
►► Epigenetic immune cell counting in human blood
samples for immunodiagnostics.209
The general stability of DNA as well as its methylation,
in addition to the small sample volume needed, provide
epigenetic-based assays the advantage of being less susceptible to challenges related to sample amount and quality,
and permit the measurement of different immune cell
subset frequencies without the need to count intact cells.
The immune cell subset-specific epigenetic markers are
developed based on highly purified, fluorescence-activated

cell sorting (FACS)-
sorted cells, obtained from whole
blood of healthy donors. Cancer is a disease affecting
the DNA of patients, including, but not limited to, DNA
strand breaks, gene duplication, and aberrant DNA methylation. In the immuno-oncology setting, this represents
a theoretical obstacle to the successful use of this technology, since the specificity of the established cell type
markers from healthy individuals could be compromised
in cancer, precluding their use, at least in tumor-affected
tissues.
►► Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark
for quantification of Tregs in unseparated melanoma
samples.210
Conclusions
There is a lack of peer-reviewed and published clinical
studies using this technology during immunotherapy
trials that independently demonstrate the consistency
and validity of enumerating various subsets of lymphocytes in the peripheral blood of patients with cancer in
comparison with fully validated, gold standard technologies like flow cytometry. However, it is theoretically an
attractive methodology and has the potential to change
research and clinical trial monitoring strategies. The cell
type specificity of epigenetic-based qPACC assays is likely
not a significant obstacle toward enumerating circulating
lymphocytes in most immune oncology trial settings. The
potential exception could be hematological malignancies,
which would warrant particular attention to signals indicating issues with assay specificity. The use of epigenetics-
based qPACC assays for the enumeration of different cell
types in tumor tissue carries a theoretical and published
risk of lacking specificity. In addition, it has no ability to
provide relevant data on spatial immune cell distribution
within a tumor, and therefore allows no direct comparison or correlation to classic or multiplex IHC.
Microbiome sequencing
The human body is inhabited by countless microorganisms that live within diverse communities specific to
each body site, including the skin, nose and mouth, eyes,
and gastrointestinal and urogenital tracts. The human
microbiome (or human microbiota) is referred to as the
collection of micro-organisms which live on and in us,
and comprised not just bacteria, but also fungi, protozoa,
and viruses. The important role the microbiome plays
in human health and disease, including oncology, is a
broadly accepted fact today:
►► The human microbiome: at the interface of health
and disease.211
Impressive progress in high-
throughput sequencing
methods used by human genome research has benefitted
the investigation of the microbiome greatly by enabling
high-throughput microbial characterization in a culture-
independent manner. The two most common methods of
sequencing used to study the microbiome are 16 S rRNA
sequencing and shotgun metagenomics.
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Genomic approaches to studying the human
microbiota.212
The 16S rRNA is part of the 30 S subunit of prokaryotic
ribosomes. The 16S ribosomal gene is understood to be
present in all bacteria and contains regions that are highly
variable between species that can be used to differentiate
between different bacteria without having to sequence
their entire genome. This approach permits targeting
of only very specific regions of the genome, dramatically
reducing the amount of sample and sequencing needed.
The main disadvantage of this technology is that it can
only identify and differentiate bacteria; it cannot be used
to detect or differentiate viruses, fungi, or protozoa.
There are different protocols and platforms available for
16S rRNA sequencing, and a more indepth analysis of
platforms can be found in the following:
►► A comprehensive benchmarking study of protocols
and sequencing platforms for 16 S rRNA community
profiling.213
►► The madness of microbiome: attempting to find
consensus “best practice” for 16 S microbiome
studies.214
Shotgun metagenomic sequencing is the other
approach most often used. During shotgun sequencing,
all DNA within a complex sample are fragmented into very
small pieces and then amplified and analyzed with NGS
technology. It permits the study of the entire genomes of
all the organisms present in a sample, including viruses,
fungi, and protozoa. Shotgun metagenomics can give
indications as to dominant gene pathways and functions,
and are less susceptible to the biases that are inherent in
targeted gene amplification.
215
►► Shotgun metagenomics, from sampling to analysis.
Different microorganisms and the microbiota, in
general, are able to increase or alleviate carcinogenesis,
alter sensitivity to cancer therapeutics, and influence
response to immunotherapy. There are several areas of
positive or negative contribution to carcinogenesis by
microbes. They include changing the balance of host cell
proliferation and death, altering immune system function, and influencing a host’s metabolism. Microbiota
can act as an adjuvant, enhancing efficacy or attenuating
toxicity of chemotherapies.
216
►► Cancer and the microbiota.
217
►► The role of microbiota in cancer therapy.
218
►► Microbiome and anticancer immunosurveillance.
A direct detrimental immunological effect has been
shown, for example, in the inhibition of NK cell killing of
various tumors by Fusobacterium nucleatum.
►► Binding of the Fap2 protein of Fusobacterium nucleatum
to human inhibitory receptor TIGIT protects tumors
from immune cell attack.219
Efforts to target the microbiota in oncology settings
should take into account that, during fecal microbiota
transplantation (FMT), adverse events (including patient
death) have been observed in attempted treatments of
recurrent or refractory Clostridium difficile infections and
other intestinal or extraintestinal disorders.
►►
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►►

Systematic review: adverse events of fecal microbiota
transplantation.220

Conclusions
Studies have demonstrated the influence of the microbiome on carcinogenesis and response to therapy.
However, it will require extensive research and resources
to obtain reliable and clinically actionable information.
The microbiota can vary considerably over time, between
individuals, and in different areas of the body. Establishing clear distinctions in regard to the cause and effect
of tumor-associated microbiota and concurrent changes
in the microbiota is essential. The prognostic potential
and theoretical value of therapeutic intervention toward
the microbiota offer the exciting possibility of new tools
to fight cancer, while making current therapies more
effective and reducing side effects.
Mitochondrial genome arrays
Mitochondrial DNA (mtDNA) genes encode proteins
that work in conjunction with nuclear genes to form the
respiratory chain complexes that represent the main
energy production structures in cells. Because of its high
susceptibility to mutations based on limited repair mechanisms existing (as compared with nuclear DNA), mtDNA
has long been suspected to contribute to carcinogenesis. Since mtDNA lacks introns, mutations always affect
coding sequences, and an accumulation of these mutations may lead to tumor formation. Research into the role
of mtDNA mutations in cancer is advancing our understanding of their contribution to carcinogenesis and their
potential value in cancer diagnosis and monitoring.
221
►► Mitochondrial DNA mutations in human disease.
►► Human mitochondrial DNA: roles of inherited and
somatic mutations.222
223
►► Mitochondria and cancer.
►► How do changes in the mtDNA and mitochondrial
dysfunction influence cancer and cancer therapy?
Challenges, opportunities and models.224
►► The landscape of mtDNA modifications in cancer: a
tale of two cities.225
High-throughput mitochondrial sequencing arrays (eg,
MitoChip by Affymetrix) are used in research and clinical
studies for the identification of mtDNA markers associated with malignancies. Using the MitoChip technique,
large numbers of mtDNA mutations have been found in
human cancers, including CRC, head and neck cancer,
bladder cancer, breast cancer, adenoid cystic carcinoma,
sessile serrated adenoma, lung cancer, urinary bladder
carcinomas, RCC, pancreatic cancers, ovarian carcinomas, gastric cancers, gliomas, and several other solid
tumors.
►► The human MitoChip: a high-throughput sequencing
microarray for mitochondrial mutation detection.226
227
►► MtDNA as a cancer marker: a finally closed chapter?
The MD Anderson Cancer Center provides an online
tool, called ‘The Cancer Mitochondrial Atlas (TCMA)
data portal’, in order to assist mitochondria-
related
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biological discoveries and clinical applications beyond
mtDNA sequencing. This open-access data portal allows
exploration of various types of molecular data:
228
►► https://ibl.mdanderson.org/tcma/
The TCMA consists of four modules: somatic mutations, nuclear transfer, copy number, and gene expression. International Cancer Genome Consortium (ICGC)
WGS data are the basis for the first three modules and
provide detailed annotations for the corresponding
seq data
features of each cancer sample. TCGA RNA-
are the basis for the last module and provide an interactive interface through which operators can visualize the
coexpression network. Operators can browse and query
molecular data by cancer type and download the data for
their own analysis.
Conclusions
The use of MitoChip to track mutations in mtDNA has
been shown to be relevant in diverse cancer settings.
However, its diagnostic, prognostic, and clinical value
is still debated in the field based on several technology-
related obstacles to standardization and relevant controls.
New NGS approaches, combined with sophisticated data
analysis to select mutations with likely functional relevance, could help to more systematically evaluate the
potential role of mtDNA mutations in tumor biology in
the future.
Epigenomic biomarker discovery
DNA methylation, histone modifications, chromatin remodeling and spatial orientation, and post-
transcriptional regulation influence gene expression
and cellular phenotype without altering the nucleotide
sequence of DNA. Collectively referred to as epigenomic
signaling, these processes orchestrate cell development
and differentiation, carcinogenesis, cancer progression,
and resistance to therapy.
An overview of the history of epigenetics, various
epigenetic processes, and their role in health and disease
can be found in the following review.
229
►► The molecular hallmarks of epigenetic control.
For detailed reviews on epigenetic processes, the
following collection is useful.
►► h t t p s : / / w w w.  c e l l .  c o m /  c e l l /  c o l l e c t i o n s /
transcription-epigenetics230
Biomarkers that detect these epigenetic processes are
crucial for diagnosis, prognostication, and therapeutic
targeting. For example, the following review enumerates
epigenomic biomarkers useful in the diagnosis and prognosis of hepatocellular carcinoma.
►► Biomarkers: what role do they play (if any) for diagnosis, prognosis and tumor response prediction for
hepatocellular carcinoma?231
In a study evaluating alternative promoter utilization
in metastatic gastric cancer, higher levels of alternative
promoter utilization predicted lower immunogenicity,
cancer immunoediting, and evasion of immune

checkpoint inhibition therapy, thus providing an epigenetic biomarker to predict response to immunotherapy.
►► Epigenomic promoter alterations predict for benefit
from immune checkpoint inhibition in metastatic
gastric cancer.232
Epigenomic profiling has become automated, miniaturized, and reproducible, with the ability to resolve at
the single cell level. Widely available epigenetic database
and processing software have now made it possible to
perform epigenomic profiling of tumors for biomarker
discovery. This paper reviews the various methods of
epigenomic biomarker discovery, their compatibility with
sample preservation techniques, automation, reproducibility, and miniaturization.
►► Genome-
wide epigenomic profiling for biomarker
discovery.233
This paper discusses the computational methods for
assessing chromatin hierarchy.
►► Computational methods for assessing chromatin
hierarchy.234
ATAC-seq
Eukaryotic DNA is extensively packaged around histone
proteins, forming nucleosomes, which are condensed
into higher levels of packaging to allow chromatin to fit
within the nucleus of a cell. Nevertheless, processes that
allow ‘open’ chromatin states, which permit transcription
factors and histone post-translational changes to influence gene expression, orchestrate active transcription.
Assay for transposase accessible chromatin with high-
throughput sequencing, or ATAC-
seq for short, is a
method for mapping chromatin accessibility genome-
wide. Hyperactive transposase Tn5 is used to cut and
ligate adaptors for high-throughput sequencing of DNA
in regions of high accessibility. This allows mapping of
‘open’ chromatin areas as well as nucleosome topology.
The following paper describes ATAC-
seq of lymphoblastoid cells.
►► ATAC-seq: a method for assaying chromatin accessibility genome-wide.235
Significant chromatin heterogeneity can exist within
a population of cells. Accuracy is enhanced when chromatin assays can be performed at a single cell level.
The following paper talks about single-
cell chromatin
profiling.
►► A rapid and robust method for single cell chromatin
accessibility profiling.236
The profiling of chromatin of different cells within a
cell population can inform cell subsets. The following
papers describe single-
cell ATAC-
seq (scATAC-
seq) in
multiple cells to cluster them.
237
►► Single-cell ATAC-seq: strength in numbers.
►► High-throughput chromatin accessibility profiling at
single-cell resolution.238
Transcript-indexed ATAC-seq is a tool by which the TCR
gene is sequenced along with ATAC-seq at the single cell
level. Transcript-indexed ATAC-seq enables an analysis of
the epigenetic landscape of a clonal T cell population and
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also enables discovery of regulatory pathways affecting T
cell function.
►► Transcript-
indexed ATAC-seq for precision immune
profiling.202
In this paper, the team has identified a programmable
and a dysfunctional chromatin state in tumor-infiltrating
T cells based on chromatin assays. They have identified
the epigenetic processes associated with dysfunctional
immune cells and surface biomarkers to identify reprogrammable T cells.
►► Chromatin states define tumour-
specific T cell
dysfunction and reprogramming.239
Studies of chromatin states using ATAC-seq in immunology to reveal epigenetic heterogeneity, the mechanistic basis of T cell dysfunction, and distinct T cell
subsets are as follows.
►► Joint single-cell DNA accessibility and protein epitope
profiling reveals environmental regulation of epigenomic heterogeneity.240
►► Newly identified T cell subsets in mechanistic studies
of food immunotherapy.241
Satpathy AT et al242 describe the use of scATAC-seq with
a droplet-based method on a widely used single-cell 10X
Chromium platform to discover cell types and regulatory
DNA elements in complex tissues. They performed scATAC-seq using bone marrow and blood samples to characterize the chromatin landscape of cell subtypes and
their differentiation trajectories. They then performed
scATAC-
seq on primary tumor tissue before and after
treatment with PD-1 blockade. The authors demonstrate
the ability to deconvolute the TME at the single cell level,
revealing subpopulations of immune cells and malignant
cells.
►► Massively parallel single-cell chromatin landscapes of
human immune cell development and intratumoral T
cell exhaustion.242
The following paper describes the various methods used
to assess chromatin accessibility, including the limitations,
advantages, and specimen requirements of each technique: micrococcal nuclease sequencing (MNase-
seq),
DNase-seq, formaldehyde-assisted isolation of regulatory
elements sequencing (FAIRE-seq), and ATAC-seq.
243
►► Chromatin accessibility: a window into the genome.
ChIP arrays (ChIP on chip) and ChIP-seq
The interaction of DNA with transcription factors and
histones affects gene expression and cell phenotype.
Chromatin immunoprecipitation (ChIP) is used widely
to establish specific DNA–protein interactions. When
ChIP is combined with whole genome DNA microarrays, the assay is known as a ChIP microarray or ChIP on
chip. A genome-wide assessment of protein–DNA interactions was made possible through ChIP arrays and led
to the discovery of epigenomic transcriptional regulation. Several tiling microarray platforms for common
model organisms were commercially developed, and
bioinformatics tools were generated to analyze data from
those platforms. Some early descriptions of methods,
20

applications, and analytical tools for ChIP on chip are
referenced in the following.
►► ChIP-chip: considerations for the design, analysis, and
application of genome-wide chromatin immunoprecipitation experiments.244
►► Chromatin immunoprecipitation for determining
the association of proteins with specific genomic
sequences in vivo.245
►► Genome-
wide profiling of PPARγ:RXR and RNA
polymerase II occupancy reveals temporal activation
of distinct metabolic pathways and changes in RXR
dimer composition during adipogenesis.246
►► rMAT-- an R/Bioconductor package for analyzing
ChIP-chip experiments.247
More recently, massive parallel sequencing of DNA
fragments crosslinked to protein has been made possible
by a newly developed high-throughput sequencing technology. This technology, referred to as ChIP-seq, represents a large advancement in the study of DNA–protein
interactions.
ChIP-seq has higher sensitivity and specificity than ChIP
on chip and can be used to analyze any sequenced species,
since it is not dependent on a microarray. It is also more
cost-effective than ChIP on chip. The use of ChIP-seq
in non-coding regions of the DNA has the potential to
identify the biological role of single nucleotide polymorphisms (SNPs) associated with a disease state.
The following study compares ChIP on chip using the
Agilent tiling microarray with ChIP-seq using the Illumina GAII.
►► ChIP-
chip vs ChIP-
seq: lessons for experimental
design and data analysis.248
The following describe ChIP-seq assays and bioinformatic tools for data analysis:
►► Practical guidelines for the comprehensive analysis of
ChIP-seq data.249
►► ChIP-
seq and beyond: new and improved methodologies to detect and characterize protein-
DNA
interactions.250
►► Identifying and mitigating bias in next-
generation
sequencing methods for chromatin biology.251
Methylation arrays
In the human body, using the same genome, at least 200
distinct cell phenotypes can be created by means of epigenomic processes. An epigenetic imprint of cell types
enhances cell recognition. In fact, the recent years have
seen the identification of cell types based on epigenomic
profiles by making use of reference methylation profiles
of known cell types from the gene expression omnibus
(GEO). In one such study, investigators performed
epigenetic deconvolution of SCCHN samples from the
TCGA, identifying different cell types in the tumors by
histoepigenetic means. By identifying various cell populations in the tumors as immune, cancer, and epidermal
cells, the investigators were able to epigenetically profile
the distinct types of SCCHN by differential methylation
analysis:
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Histoepigenetic analysis of HPV- and tobacco-
associated head and neck cancer identifies both
specific and common therapeutic targets
subtype-
despite divergent microenvironments.252
Several methylated genes serve as biomarkers of disease
diagnosis, prognosis, and therapeutic targeting. With the
availability of epigenome-wide methylation arrays, a much
more amplified biomarker discovery platform is available.
The computational analysis of DNA methylation data
involves multiple steps of data processing. The following
papers describe the use of Illumina-based Infinium DNA
methylation BeadChip assays, which are considered to be
the gold standard method for DNA methylation analysis.
These assays provide quantitative measurement of DNA
methylation levels in a predetermined set of cytosine residues using a microarray format. With advancing capabilities and demands, and increasing numbers of target CpG
sites, the kits have advanced from HumanMethylation
27K BeadChip (27K array) to HumanMethylation 450K
(450K array) and more recently the Infinium MethylationEPIC (850K array). The following reviews describe the
steps involved in data acquisition and processing.
►► Review of processing and analysis methods for DNA
methylation array data.253
►► Computational and statistical analysis of array-
based
DNA methylation data.254
In a multicenter study based in Europe, investigators
have successfully identified and validated a DNA methylation signature, termed EPIMMUNE, associated with
clinical benefit from anti-PD-1 blockade in patients with
stage IV lung cancer. Among the methylated genes, forkhead box P1 (FOXP1) was confirmed to be a predictor of
clinical benefit from anti-PD-1 therapies. The epigenetic
signature was not associated with the PD-L1 status, mutational load, or CD8 immunostaining.
►► Epigenetic prediction of response to anti-PD-1 treatment in non-
small-
cell lung cancer: a multicentre,
retrospective analysis.255
When compared with studies that require live cells for
immune subset quantification and monitoring, assessing
gene methylation by epigenetic assays to identify cell
subsets is a more feasible approach. The same principle
can be used to characterize the cell population of tumor
tissue as well.
►► Novel technologies and emerging biomarkers for
personalized cancer immunotherapy.7
PBMCs and T cells from patients with HCC have been
shown to have a DNA methylation signature distinct from
those who do not have HCC. This methylation signature
in the host immune cells deepens as the HCC advances.
►► The signature of liver cancer in immune cells DNA
methylation.256
►►

microRNA arrays
Overwhelming portions of the human DNA do not
encode protein. The RNA resulting from the transcription of approximately 98% of DNA is non-coding RNA
(ncRNA). In the early 2000s, the role of ncRNAs as they

affect translation of proteins started to emerge. Further
study revealed a large network of interactions between
ncRNA and the cell physiological machinery. This has
led to a new understanding of what used to be considered ‘junk’ DNA and RNA. These are now recognized as
important players in the regulation of the cell machinery
and as oncogenic drivers and suppressors.
257
►► Non-coding RNA networks in cancer.
microRNA (miRNA) are 22-
nucleotide short RNA
molecules that are highly conserved through evolution.
miRNA binds to mRNA transcripts of a gene, which leads
to cleavage of the mRNA or shutdown of gene translation.
miRNAs are active participants in normal cellular, developmental, and host environment processes such as intercellular communication through exosomes. Additionally,
these tiny molecules play a fascinating role in cancer, as
they have the powerful ability to orchestrate carcinogenesis and therapy resistance in cancer. Some miRNAs may
stimulate an oncogenic process directly by acting as a
ligand, termed onco-miRNAs (such as miR-21/miR-29a),
while others such as miR34a act as tumor suppressors. For
a detailed review on this subject, refer to the following.
258
►► The role of microRNAs in human cancer.
Circulating and exosomal miRNAs can be used as
diagnostic biomarkers for diseases such as cancer. The
following reviews discuss the process of developing
miRNAs as biomarkers, various profiling platforms,
sample preparation, and analytical strategies.
259
►► MicroRNA as biomarkers and diagnostics.
260
►► Potential pitfalls in microRNA profiling.
The following reviews outline the role of miRNAs in
mediating immune responses by influencing cellular
signaling in immune cells, influencing both innate and
adaptive immunity.
►► MiRNAs: dynamic regulators of immune cell functions in inflammation and cancer.261
►► Nuclear functions of mammalian microRNAs in gene
regulation, immunity and cancer.262
►► Extracellular RNAs: a secret arm of immune system
regulation.263
264
►► miRNA regulation of innate immunity.
►► MicroRNAs as regulatory elements in immune system
logic.265
The following is an excellent review of the role of
miRNAs in oncogenesis and therapy resistance in melanoma. The authors describe an miRNA signature that
affects angiogenic and inflammatory pathways and
predicts resistance to both targeted and immunotherapy,
highlighting this as a biomarker of resistance and a potential therapeutic target.
►► MicroRNA-
driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma.266
Studies that successfully sought and identified miRNA
biomarker signatures in relation to immunotherapy in a
variety of settings are listed below.
►► Identification of a microRNA signature in dendritic
cell vaccines for cancer immunotherapy.267
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Circulating immune cell and microRNA in patients
with uveal melanoma developing metastatic disease.268
miRNA can also be used as therapeutic targets.
►► Sequence-
specific knockdown of EWS-
FLI1 by
targeted, nonviral delivery of small interfering RNA
inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma.269
►► Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.270

►►

Conclusions
Epigenetic biomarker discovery has an expansive reach
in clinical practice for diagnostic, prognostic, and therapeutic purposes. Multiple epigenetic processes such as
DNA methylation, histone post-
translational changes,
chromatin remodeling, and ncRNA production have
been described in the context of normal tissue development, cancer, and immunology. Sample processing
and preservation, miniaturization, and automation have
improved the ability to perform large-scale reproducible
epigenome-wide biomarker assays to define the epigenetic phenotype of cells. In conjunction with refined
bioinformatics analytical processes, epigenetics has been
successfully applied toward biomarker discovery in immunology. A shared knowledge of a growing epigenomic
database, developed in conjunction with a much larger
and more mature genomic database, facilitates establishment of epigenomic signatures of cell subsets, drug resistance, and other immunological biomarkers. Epigenetic
changes can serve as biomarkers of diagnosis and prognosis, and are attractive therapeutic targets.
Transcriptomic biomarker discovery
RNA sequencing
With the advent of NGS, RNA-
seq has become mainstream in transcriptome analysis spanning basic and translational research. This methodology enabled sequencing
and quantification of the transcriptional portraits of
individual cells or thousands of samples, linking cellular
and molecular phenotypes. Below is the first article that
reported RNA-seq.
►► Mapping and quantifying mammalian transcriptomes
by RNA-seq.271
The following articles provide a high-level overview
of RNA-seq, summarizing advantages over existing transcriptomic platforms and challenges. Technological
advancements are covered, including improvements in
transcription start site mapping, strand-specific measurements, gene fusion detection, small RNA characterization, detection of alternative splicing events, direct
RNA sequencing, and approaches that enable profiling
of small RNA quantities. Also reviewed are methods
and tools developed for preprocessing high-throughput
RNA-
seq data and the analysis of differential gene
expression.
272
►► RNA-seq: a revolutionary tool for transcriptomics.
►► RNA
sequencing: advances, challenges and
opportunities.273
22

From RNA-
seq reads to differential expression
results.274
These articles outline a historical timeline of transcriptomics, summarize various protocols and computational
tools for RNA-seq, discuss the potential clinical utility of
transcriptomic approaches, provide a useful toolbox with
resources to analyze cancer transcriptomics, outline the
lack of appropriate reference standards for validating
RNA-seq, and illustrate the overabundance of competing
computational tools.
►► Cancer transcriptome profiling at the juncture of clinical translation.275
►► Translating RNA sequencing into clinical diagnostics:
opportunities and challenges.276
►► Reference
standards
for
next-
generation
sequencing.277
This article provides links to resources (Ensembl
Compara, Gencode, Mouse Genomes Project, Mouse
Phenome Database, OMIM (Online Mendelian Inheritance in Man), Rfam (RNA families database), Blueprint,
ENCODE (Encyclopedia of DNA Elements), FANTOM
(Functional Annotation of the Mammalian Genome),
GTEx (Genotype-
Tissue Expression) project, Human
Cell Atlas Consortium, and so on) to help interrogate
human and mouse transcriptomics.
278
►► Comparative transcriptomics in human and mouse.
►►

EdgeSeq
EdgeSeq is a gene expression analysis platform developed
by HTG which combines quantitative nuclease protection assay technology with NGS, using small amounts
of starting material and delivering reproducible GEPs
from poor-quality formalin-fixed paraffin-embedded
(FFPE) tissue samples including haematoxylin and eosin
(H&E)-stained tumor specimens. The EdgeSeq platform
is capable of generating reliable expression data for thousands of genes from as little as 1 mm2 FFPE tissue and
crude FFPE tissue lysates equivalent to surface areas as
low as 0.31 mm2 of a 5 mm section, and can be particularly useful to interrogate biomarkers in oncology clinical
trials, which often lack a sufficient amount of high-quality
tumor tissue for other techniques.
►► Reliable gene expression profiling from small and
hematoxylin and eosin-
stained clinical formalin-
fixed, paraffin-embedded specimens using the HTG
EdgeSeq platform.279
►► EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.168
Conclusions
RNA-
seq is an open platform technology that has a
number of potential advantages over gene expression
microarrays, including an increased dynamic range of
expression, measurement of focal changes (such as single
nucleotide variants, insertions, and deletions), detection of different transcript isoforms, splice variants, and
chimeric gene fusions (including previously unidentified
transcripts and/or RNA species such as circular RNAs),
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and application to samples obtained from any biological
species. As the cost of RNA-seq continues to decrease,
this platform will most likely replace many applications
focused on the analysis of transcriptome structure and
dynamics. RNA-seq-based assays also have the potential
to become a diagnostic platform in different therapeutic
areas, including oncology. However, the establishment of
appropriate quality standards and the adoption of best
practices will be necessary to transform this exciting technology from a purely exploratory tool into a reliable diagnostic platform.
Single-cell gene expression analysis
The application of RNA-
seq to single cells was first
published here.
►► mRNA-
seq whole-
transcriptome analysis of a single
cell.280
The following two articles provide an overview of
scRNA-seq applications in immunology; the second paper
contains links to useful databases such as the Differentiation Map (DMAP) project, Hematopoietic Stem and
Progenitor Cell Atlas, Illumina Body Map Expression
Atlas, Immunological Genome Project, and Portal for
multiple scRNA-seq data.
281
►► A single-cell sequencing guide for immunologists.
►► Single-cell RNA sequencing to explore immune cell
heterogeneity.282
scRNA-seq has the potential to identify rare immune
cell subsets as well as unique cell populations and transcriptomic signatures associated with response or resistance to immunotherapy in humans and mice.
►► Single-cell transcriptomics in cancer immunobiology:
the future of precision oncology.283
►► Single-cell RNA-seq reveals new types of human blood
dendritic cells, monocytes, and progenitors.284
►► A cancer cell program promotes T cell exclusion and
resistance to checkpoint blockade.173
►► Defining T cell states associated with response to
checkpoint immunotherapy in melanoma.150
►► High-
dimensional analysis delineates myeloid and
lymphoid compartment remodeling during successful
immune-checkpoint cancer therapy.285
These articles provide an overview of currently available scRNA-seq methods and describe methods for the
isolation of individual cells for scRNA-seq, construction
of cDNA libraries, and computational analysis. They also
discuss current applications and challenges associated
with scRNA-seq.
286
►► Single-cell RNA-seq: advances and future challenges
►► The technology and biology of single-
cell RNA
sequencing.287
►► Design and analysis of single-
cell sequencing
experiments.288
A number of biological and technical factors should be
taken into consideration to measure the transcriptomic
profiles of single cells, and computational methods can
be developed to remove technical effects and dissect
factors underlying biological variation.

Revealing the vectors of cellular identity with single-
cell genomics.289
►► Exponential scaling of single-cell RNA-seq in the past
decade.290
►► Computational and analytical challenges in single-cell
transcriptomics.291
►► Design and computational analysis of single-cell RNA-
sequencing experiments.292
►► Challenges in unsupervised clustering of single-
cell
RNA-seq data.293
Clustered regularly interspaced short palindromic
repeats (CRISPR)-
based genetic screens have been
increasingly used in basic research and drug discovery;
their use, however, has been restricted to the analysis
of simple cellular phenotypes in bulk cell populations.
Multiple screening strategies are currently focused on
combining CRISPR-based gene alterations with scRNA-seq
to enable high-content molecular analysis with single-cell
resolution, including cell lineage tracing.
►► Dissecting immune circuits by linking CRISPR-pooled
screens with single-cell RNA-seq.294
►► Perturb-
Seq: dissecting molecular circuits with scalable single-
cell RNA profiling of pooled genetic
screens.295
►► A multiplexed single-cell CRISPR screening platform
enables systematic dissection of the unfolded protein
response.296
►► Whole-
organism clone tracing using single-
cell
sequencing.297
►► Simultaneous lineage tracing and cell-type identification using CRISPR-Cas9-induced genetic scars.298
►► Simultaneous single-cell profiling of lineages and cell
types in the vertebrate brain.299
Multimodal data are generated by single-cell transcriptomics, genomics, epigenomics, and proteomics methods
to enable integrative analyses. Emerging technologies also
allow spatial single-cell gene expression analysis by RNA
in situ or other methods such as STARmap, SpatialDE, or
trendsceek to allow assessment of the spatial organization
of individual cells within a tissue. STARmap is a combination of hydrogel-tissue chemistry, targeted signal amplification, and in situ sequencing which enables mRNA
quantification in single cells and positional mapping of
cell types. SpatialDE and trendsceek employ statistical
methods from geostatistics, astronomy, and materials
physics to develop clustering approaches that enable
spatial gene expression analysis.
300
►► Integrative single-cell analysis.
301
►► Spatially resolved transcriptomics and beyond.
►► Three-dimensional intact-tissue sequencing of single-
cell transcriptional states.302
303
►► SpatialDE: identification of spatially variable genes.
►► Identification of spatial expression trends in single-
cell gene expression data.304
►►

Conclusions
Single-cell transcriptomic analysis is rapidly transforming
the field of biomedical research. While the promise and
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potential of this technology are apparent, several challenges remain. Efforts are underway to improve single-
cell partitioning and whole transcriptome amplification,
and to increase the sensitivity of scRNA-seq, which would
allow detection of low-abundance RNAs and rare cells
in the presence of biological and technical noise. An
appropriate sample size and measurement of sufficient
numbers of single-cell events are equally important to
increase the accuracy and precision of scRNA-seq analyses.
There is also a need for standardized scRNA-seq protocols, harmonized computational pipelines (including
methods capable of resolving spatial single-cell transcriptomics), integrated single-cell data across experiments or
modalities, and repositories dedicated to the massive and
constantly increasing amounts of scRNA-seq data.
Hybridization and PCR-based gene expression platforms
Transcriptome profiling with microarrays
While commonly used DNA arrays have become quickly
outdated with the advent of RNA-seq, more advanced
gene expression microarrays (eg, Affymetrix Human
Transcriptome Array V.2.0 (HTA V.2.0), Clariom D and
S arrays), which leverage the latest transcriptome data
from multiple databases, are simple and fast tools for
whole-transcriptome expression profiling and biomarker
discovery. The Clariom D array is based on differential
exon usage resulting from alternative splicing; this platform may be advantageous for the assessment of millions
of distinct sequences and could be particularly useful in
detecting and quantifying low abundance transcripts, or
rare alternative splice variants. It is also worth noting that
Clariom D arrays require very low RNA input and are
compatible with formalin-fixed biological samples.
►► https://www.  t hermofisher.  c om/  u s/  e n/  h ome/  l ife-
science/microarray-analysis/transcriptome-profiling-
microarrays/arrays-rna-seq.html305
HTA V.2.0 was used for gene expression profiling to
allow analysis of coding as well as non-coding and alternatively spliced transcripts in peripheral T cells isolated
from patients with melanoma treated with anti-
PD-1,
anti-CTLA-4, and combinations of both antibodies. The
results of this analysis revealed quantitatively and qualitatively distinct gene expression signatures associated with
monotherapy or combination treatment.
►► Combination therapy with anti-CTLA-4 and anti-PD-1
leads to distinct immunologic changes in vivo.176
nCounter and Digital Spatial Profiler
The nCounter gene expression system developed by
NanoString enables enumeration of individual mRNAs
using unique barcoding technology. Advantages over
existing platforms include direct measurement of
mRNA expression levels without enzymatic reactions,
sensitivity coupled with high multiplex capability (up
to 800 transcripts), and digital readout. Because detection probes in the nCounter analysis target relatively
short mRNA sequences, this platform demonstrates
outstanding performance in FFPE tissue samples and can
24

be run on both purified RNA and tissue/cell lysates. It
has also demonstrated utility in preclinical research using
different species (mouse, rhesus/cynomolgus monkey)
and sample types (tumor tissue, whole blood).
►► Direct multiplexed measurement of gene expression
with color-coded probe pairs.306
►► The CDK4/6 inhibitor abemaciclib induces a T cell
inflamed tumor microenvironment and enhances the
efficacy of PD-L1 checkpoint blockade.307
►► A conserved transcriptional response to intranasal
Ebola virus exposure in nonhuman primates prior to
onset of fever.308
►► Evaluating robustness and sensitivity of the NanoString technologies nCounter platform to enable multiplexed gene expression analysis of clinical samples.309
The nCounter platform has been used to interrogate
predictive and pharmacodynamic biomarkers in immuno-
oncology clinical trials.
►► IFN-γ-related mRNA profile predicts clinical response
to PD-1 blockade.164
►► Pan-tumor genomic biomarkers for PD-1 checkpoint
blockade-based immunotherapy.118
►► Analysis of immune signatures in longitudinal tumor
samples yields insight into biomarkers of response
and mechanisms of resistance to immune checkpoint
blockade.143
Digital Spatial Profiler (DSP) is another platform
developed by NanoString aimed at assisting with positional information about mRNA/protein expression in a
tissue sample. DSP is essentially a variation of multiplex
mRNA in situ hybridization and IHC, but is based on the
nCounter barcoding technology. The platform is capable
of providing spatially resolved, digital characterization of
proteins or mRNA in a highly multiplexed (up to 1000-
plex) assay. The following two articles exemplify the translational utility of the DSP assay.
►► Neoadjuvant immune checkpoint blockade in high-
risk resectable melanoma.310
►► Neoadjuvant vs adjuvant ipilimumab plus nivolumab
in macroscopic stage III melanoma.311
QuantiGene Plex
The QuantiGene Plex (QGP) gene expression assay
combines branched DNA (bDNA) technology with the
Luminex fluorescent microbead-
based platform. It uses
cooperative hybridization, which allows for an exceptionally high degree of assay specificity by using multiple probes
that hybridize to the same gene. The QGP assay is amenable
to high-throughput analysis in a 96-well or 384-well format
and is capable of multiplexing up to 80 targets in one
well. Similar to nCounter, this platform is compatible with
formalin-fixed material or samples with degraded RNA and
can be run on both purified RNA and tissue/cell lysates.
►► A multiplex branched DNA assay for parallel quantitative gene expression profiling.312
►► QuantiGene Plex represents a promising diagnostic
tool for cell-of-origin subtyping of diffuse large B-cell
lymphoma.313
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►►

The CDK4/6 inhibitor abemaciclib induces a T cell
inflamed tumor microenvironment and enhances the
efficacy of PD-L1 checkpoint blockade.307

High-throughput quantitative PCR
The microfluidics-
based Biomark HD (Fluidigm) is a
moderate/high-throughput qPCR system which is capable
of analyzing the expression of multiple genes across
multiple samples (up to 96×96) on a single plate with an
integrated fluidic circuit format. Compared with plate-
based high-
throughput qPCR platforms, the Biomark
HD provides excellent flexibility coupled with time-
effectiveness and cost-effectiveness to explore a range of
transcriptomic biomarkers in clinical samples. It is capable
of analyzing samples with very low RNA input. However, as
has been observed with all PCR assays, the Biomark HD
demonstrates superior performance on RNA isolated from
snap-frozen rather than formalin-fixed tissue samples.
The below referenced articles provide examples of
high-throughput qPCR analysis of formalin-fixed tumor
biopsy samples using Biomark HD as part of biomarker
assessments in clinical trials of anti-PD-L1 (atezolizumab).
►► Predictive correlates of response to the anti-
PD-
L1
antibody MPDL3280A in cancer patients.87
►► Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):
a multicentre, open-
label, phase 2 randomised
controlled trial.33
Conclusions
Although RNA-seq has been increasingly used in biomedical research and may be advantageous in biomarker
discovery as an agnostic hypothesis-generating tool, under
certain circumstances the aforementioned gene expression platforms may provide significant value, particularly
in situations when limited amounts of tissue material or
formalin-fixed tissue samples are available. While exon
junction (Clariom D) arrays and nCounter assays allow
broad interrogation of transcriptomic changes, QGP and
high-
throughput-
qPCR assays are more fit for hypothesis testing or interrogation of specific transcriptomic
biomarkers or signatures.
Proteomic biomarkers discovery: detection techniques
ELISPOT
ELISPOT allows the detection of functionally active,
antigen-specific immune cells on the single cell level by
capturing the released analyte of interest on a membrane,
which is then made visible for enumeration. The assay
format as used today for the detection of cytokine-
secreting cells was first described in 1988.
►► Reverse ELISPOT assay for clonal analysis of cytokine
production. I. Enumeration of gamma interferon-
secreting cells.314
As a generally easy-to-perform assay with exceptional
sensitivity, ELISPOT has remained a common assay
choice for basic, translational, and clinical applications in
a variety of fields, with surprisingly little change to the

basic procedure. A comprehensive review of the technique can be found here.
►► Elispot for rookies (and experts too), techniques in
life science and biomedicine for the non-expert.315
ELISPOT has been the subject of broad harmonization
efforts.
►► Results and harmonization guidelines from two
large-
scale international Elispot proficiency panels
conducted by the Cancer Vaccine Consortium (CVC/
SVI).316
►► Guidelines for the automated evaluation of Elispot
assays.317
With the introduction of fluorophores for spot detection (FluoroSpot), multiplexing is now possible and is
currently being used for the polyfunctional assessment of
cells for up to four different cytokines, resulting in the
potential detection of 15 subpopulations. The application of peptide-tagged antigen and anti-tag detection antibodies can be used to identify multiple antibody-secreting
cells with different antigen specificities.
►► An antigen-specific, four-color, B-cell FluoroSpot assay
utilizing tagged antigens for detection.318
While the analysis of ELISPOT and FluoroSpot has
largely depended on image analyzers, a new analysis algorithm uses data directly from the camera chip, avoiding
any evaluation bias and providing spot volume data, a
relative measure of the amount of cytokine released by
a single cell.
►► Cell detection by functional inverse diffusion and
non-negative group sparsity—part I-II.319
An ELISPOT-specific statistical test for response definition has been developed, and an online tool is available to
the community for free.
320
►► http://www.scharp.org/zoe/runDFR/
Many publications exist using ELISPOT for immune
monitoring purposes in immunotherapeutic cancer
trials, including the neoantigen arena.
►► An immunogenic personal neoantigen vaccine for
patients with melanoma.321
The monitoring of antigen-specific immune responses
in patients undergoing immunotherapy can be performed
using ex vivo isolated T cells without the bias of in vitro
stimulation.
►► Immunological markers and clinical outcome of
advanced melanoma patients receiving ipilimumab
plus fotemustine in the NIBIT-M1 study.322
Conclusions
ELISPOT and FluoroSpot are useful tools for functionally
assessing immune cells at the single cell level, and also
allow the polyfunctional analysis of cells. It is, however,
generally not possible to do phenotypic analysis of cells
with these methods.
ELISA
The Enzyme Linked Immunosorbent Assay (ELISA) is
a method first described by Weiland323 in 1978 to detect

Hu-Lieskovan S, et al. J Immunother Cancer 2020;8:e000705. doi:10.1136/jitc-2020-000705

25

Open access
and quantify the presence of analytes, including antibodies, antigens, proteins, and glycoproteins in biological
samples.
►► The enzyme-linked immunosorbent assay (ELISA)--a
new serodiagnostic method for the detection of parasitic infections.323
This method has been widely used for routine diagnosis
of viral diseases, such as HIV or HBV infection, but also
for pregnancy tests and quantification of soluble molecules in patients’ serum, plasma, urine, or cellular supernatants. ELISAs can be performed in 48-
well, 96-
well,
and 384-well plates, allowing concomitant interrogation
of multiple samples, as well as monitoring of changes in
analyte concentration at different timepoints.
The most common types of ELISA are the (1) indirect
and (2) sandwich methods. The indirect ELISA is generally
used to detect antibodies in the serum, plasma, or supernatants. Cancer patients’ humoral immune responses
against specific tumor-associated antigens (TAAs) have
been assessed with the aim of monitoring changes in
immune responses over the course of treatments and to
find possible associations with clinical outcome. Humoral
responses against shared TAAs, such as NY-ESO-1, p53,
and SOX2, have been monitored in serum or plasma of
patients with cancer using ELISAs.
324
►► Autoantibodies against cancer antigens.
►► Integrated NY-
ESO-1 antibody and CD8+ T cell
responses correlate with clinical benefit in advanced
melanoma patients treated with ipilimumab.325
►► Ipilimumab increases activated T cells and enhances
humoral immunity in patients with advanced
melanoma.326
►► Mechanistic insight into the TH1-
biased immune
response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane
vesicles.327
The sandwich method allows the detection of soluble
antigens. In this technique, an analyte-specific antibody is
coated on the microtiter well. The sample to be analyzed
is then added to the well, forming an antigen-antibody
complex. A second enzyme-conjugated antibody specific
for a different epitope on the antigen is added and, in
the presence of an enzyme-specific substrate, the colorimetric reaction is developed. This method allows detection of soluble factors in serum or plasma, including
cytokines, immunomodulating molecules, and growth
factors, as well as their changes in association with the
clinical outcome of patients with cancer undergoing
immunotherapy treatments.
►► Contribution of humoral immune responses to the
antitumor effects mediated by anthracyclines.328
►► Soluble NKG2D ligands are biomarkers associated
with the clinical outcome to immune checkpoint
blockade therapy of metastatic melanoma patients.329
►► Immunological markers and clinical outcome of
advanced melanoma patients receiving ipilimumab
plus fotemustine in the NIBIT-M1 study.322
26

A pilot phase I study combining peptide-based vaccination and NGR-
hTNF vessel targeting therapy in
metastatic melanoma.330
The sensitivity of ELISA can be augmented through
the amplified luminescent proximity homogeneous
assay (ALPHA). This chemiluminescence-based method
can detect analytes at the level of femtograms, reduces
washing steps, and is based on the usage of acceptor
beads coated with the primary antibody specific for the
coated donor beads, and
defined antigen, streptavidin-
the secondary antibody conjugated to streptavidin.

►►

Conclusions
ELISA is a simple methodology that provides rapid
results. No antigen purification is required prior to
measurement and specificity is increased by using two
antibodies. Flexibility and sensitivity are increased by the
application of ALPHA technology, allowing the usage of a
minimal amount (5–20 µL) of starting material and large-
scale screening (96-well, 384-well, or 1536-well format).
However, these methods are limited by the detection of
one analyte at a time and do not allow multiplex high-
throughput screening.
Multiplexed immunoassays
In the late 1990s, the recently founded Luminex Corporation proposed a commercial FlowMetrix platform for
the simultaneous detection of up to 64 analytes using a
conventional flow cytometer. The technology relied on
64 distinct sets of fluorescent beads, each coupled with
either an antigen, or an antibody, or a nucleic acid, and
used as the solid phase of immunoassays or hybridization.
The mixing of these distinct sets allowed for the simultaneous monitoring of independent assays using a flow
cytometer equipped with digital signal processing.
►► Advanced multiplexed analysis with the FlowMetrix
system.331
This seminal publication laid the basis of the future
development of high dimension protein and nucleic
acid profiling platforms. In its current implementation, the Luminex platform is able to monitor 500
simultaneous assays. The versatility of the platform has
given rise to several applications in cancer research. A
comprehensive review of the origin and evolution of
multiplex assays has recently been discussed by Graham
H et al.332
►► The
genesis and evolution of bead-
based
multiplexing.322
The simplest application consists of the evaluation of
cytokine and chemokine profiles in the serum or plasma
of patients affected by cancers.
►► The plasma levels of 12 cytokines and growth factors
in patients with gastric cancer.333
►► Cytokine comparisons between women with breast
cancer and women with a negative breast biopsy.334
Luminex assays or other multiplexed bead array embodiments, such as the Cytokine Bead Array (Becton Dickinson), performed on peripheral blood or other body
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fluids, have been used as prognostic/diagnostic tools in
several cancers.
Ovarian cancer
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.335
►► Diagnostic markers for early detection of ovarian
cancer.336
►► Multiplexed bead-based immunoassay of four serum
biomarkers for diagnosis of ovarian cancer.337
►► Serum expression level of cytokine and chemokine
correlates with progression of human ovarian
cancer.338
►►

Breast cancer
The multiplex bead array approach to identifying
serum biomarkers associated with breast cancer.339

►►

Nasopharyngeal carcinoma
Prognostic role of serum cytokines in patients with
nasopharyngeal carcinoma.340

►►

Gastric cancer
Serum biomarker panels for diagnosis of gastric
cancer.341

►►

Colorectal cancer
►► Diagnostic performance of a novel multiplex immunoassay in colorectal cancer.342
Non-Hodgkin lymphoma
Cytokines in serum in relation to future non-Hodgkin
lymphoma risk: evidence for associations by histologic
subtype.343

►►

Non-small cell lung carcinoma
A novel detection method of non-
small cell lung
cancer using multiplexed bead-
based serum
biomarker profiling.344
►► Determination of 16 serum angiogenic factors in
stage I non-small cell lung cancer using a bead-based
multiplex immunoassay.345
►► Salivary cytokine panel indicative of non-
small cell
lung cancer.346
►► Evaluation of saliva and plasma cytokine biomarkers
in patients with oral squamous cell carcinoma.347
Multiplexed immunoassays have entered the arena of
personalized medicine to monitor response to therapy in
patients affected by NSCLC.
►► Differential expression of circulating biomarkers of
tumor phenotype and outcomes in previously treated
non-small cell lung cancer patients receiving erlotinib
vs cytotoxic chemotherapy.348
In addition to biomarker discovery, multiplexed bead
assays have been used to characterize the phosphorylation pathways whose dysregulation is often involved
in carcinogenesis. A technical chapter describing this
approach can be found in the following.
►►

Utilizing the Luminex magnetic bead-based suspension array for rapid multiplexed phosphoprotein
quantification.349
The ability of Luminex assays to monitor DNA hybridization has been exploited to characterize mutations in
cancer cells.
►► Clinical validation of newly developed multiplex
kit using Luminex xMAP technology for detecting
simultaneous RAS and BRAF mutations in colorectal
cancer: results of the RASKET-B study.350
Bead multiplexing and PCR multiplexing have been
combined in multiplex liquid bead arrays used for the
molecular characterization of circulating tumor cells
(CTCs).
►► Molecular characterization of circulating tumor cells
in breast cancer by a liquid bead array hybridization
assay.351
►► Development and validation of multiplex liquid bead
array assay for the simultaneous expression of 14
genes in circulating tumor cells.352
Another multiplex immunoassay platform, Olink, uses
proximity extension assay (PEA) technology to achieve
specificity for 92 analytes in a single panel, with multiple
disease-specific panels available. PEA uses a pair of non-
cross-blocking antibodies for each target, which are tagged
with complementary oligonucleotides. Binding of the antibody pair allows for the complementary sequences to pair
and to be extended to create a PCR template. Readout
is on the Fluidigm Biomark microfluidic qPCR platform,
using a 96.96 array (96 assay targets × 96 samples/controls).
Because of the availability of an immune oncology panel,
Olink is being used with increasing frequency in immunotherapy trial monitoring, including in the CIMAC/CIDC
network. For example, this CAR T cell study used Olink
to find multiple plasma proteins that correlated with
responder status, including IL-12.
►► A phase I/IIa trial using CD19-
targeted third-
generation CAR T cells for lymphoma and leukemia.353
►►

Conclusions
Multiplexed bead arrays are a useful tool in cancer
research, with applications ranging from diagnosis, disease
monitoring, predictive and prognostic biomarkers, to the
molecular characterization of cancer cells at the transcriptome and protein levels.
Cytometry-based methods
Flow cytometry remains a very powerful tool for multiparameter analysis of immune cells in both blood and
tumor tissue. This section highlights advances in flow
cytometry-related methodology that impacts the field of
immunotherapy.
High-parameter flow cytometry
The number of parameters that can be measured in
parallel by multicolor flow cytometry has grown rapidly
in the last 8 years, mostly due to the development of
new polymer-based dyes with tunable emission peaks, as
described in the following.
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Brilliant violet fluorophores: a new class of ultrabright
fluorescent compounds for immunofluorescence
experiments.354
At the same time, new instrumentation has now made
it possible to perform flow cytometry with over 18 colors
(the previous limit), the limiting factor currently being
the fluorochromes. This has allowed the simultaneous
monitoring of a large number of immune checkpoint
molecules on a wide array of immune cell types, as shown
with this 28-color panel.
►► OMIP-050: A 28-
color/30-
parameter fluorescence
flow cytometry panel to enumerate and characterize
cells expressing a wide array of immune checkpoint
molecules.355
Another notable development in the field is flow cytometers that use spectral deconvolution rather than a single
bandpass filter/detector for each fluorochrome. In
effect, spectral cytometry uses the shape of the complete
emission spectrum to determine the signals derived from
each fluorochrome on each cell. This has allowed resolution of fluorochromes that would otherwise be very difficult to distinguish. A review of how this method has been
applied to cells derived from solid tissues, a common
application for tumor immune monitoring, is given in
the following.
►► Spectral cytometry has unique properties allowing
multicolor analysis of cell suspensions isolated from
solid tissues.356
The use of standardized multicolor immune monitoring
panels to profile immune cell phenotypes and functions
in blood and tumor is exemplified in this recent publication in breast cancer.
►► Examining peripheral and tumor cellular immunome
in patients with cancer.357
►►

Conclusions
Fluorescence-based flow cytometry continues to evolve,
with new dyes and new instrumentation, including spectral flow cytometers that increase the number of parallel
parameters that can be measured, as well as the resolution of those parameters.
Mass cytometry
Flow cytometry is performed using fluorescently tagged
antibodies and other fluorescent probes. More recently,
the use of heavy metal ion tags, which are chelated to
a polymer backbone and read out using time-of-flight
mass spectrometry, has been introduced. This method
is known as mass cytometry, or CyTOF (Cytometry by
Time of Flight). While offering a significantly slower
throughput than fluorescence cytometry, it provides the
dual advantages of allowing for more antibody specificities to be used in parallel, along with much reduced spillover between detector channels. The method was first
described in the following papers.
►► Development of analytical methods for multiplex
bio-
assay with inductively coupled plasma mass
spectrometry.358
28

Flow cytometer with mass spectrometer detection for
massively multiplexed single-cell biomarker assay.359
CyTOF technology was first applied to the study of the
immune system in 2010, using a panel of 32 antibodies on
human bone marrow cells.
►► Single-
cell mass cytometry of differential immune
and drug responses across a human hematopoietic
continuum.360
The number of available mass tags has since grown
to over 40, with many publications in different disease
settings. It has been used to study signaling in leukemic
cells, as well as immune signatures in PBMCs in the
context of immunotherapy, as in the following representative publications.
►► Mass cytometric functional profiling of acute myeloid
leukemia defines cell-cycle and immunophenotypic
properties that correlate with known responses to
therapy.361
►► Data-
driven phenotypic dissection of AML reveals
progenitor-like cells that correlate with prognosis.362
►► Distinct predictive biomarker candidates for response
to anti-
CTLA-4 and anti-
PD-1 immunotherapy in
melanoma patients.54
Mass cytometry has also been applied to the study of
immune cells infiltrating tumor tissue, as in the following
recent publications.
►► Interlesional diversity of T cell receptors in melanoma
with immune checkpoints enriched in tissue-resident
memory T cells.363
364
►► An immune atlas of clear cell renal cell carcinoma.
A review of technology and important concepts for
CyTOF data analysis has been recently published.
365
►► The anatomy of single cell mass cytometry data.
The above review also links to a website containing a
tutorial on mass cytometry data analysis and various tools
for the same.
366
►► http://cytof.biosurf.org/
A recent study has made available an ‘Antibody Staining
Data Set’ which shows the estimated expression level of
326 cell-
surface proteins on 28 different immune cell
types, on fresh or fixed cells. The interactive heat map
tool can be viewed at the following.
►► https:// a pp. a strolabediagnostics. c om/ a ntibody_  s taining_  d ata_  s et%  2 3:~:  t ext=  T he_  A ntibody_  S taining_  D ata_  S et,  s ubsets_  a t_  s ingle-  c ell_
resolution367

►►

Conclusions
Mass cytometry, while posing some technical challenges,
allows for the use of more antibody specificities than
fluorescence flow cytometry, and with much less spillover
between detector channels. It is well suited to comprehensive analyses of immune cells in tissues such as blood,
lymph nodes, or tumor. However, see multiplexed ion
beam imaging in the ‘Mass spectrometry for tissue multiplexing’ section for an alternative approach to highly
multiplexed analysis of tumor tissue, which preserves the
spatial orientation of the tissue cells.

Hu-Lieskovan S, et al. J Immunother Cancer 2020;8:e000705. doi:10.1136/jitc-2020-000705

Open access
Multimers
Multimeric forms of MHC–peptide complexes can be
identified to stain T cells specific for a given MHC–
peptide combination. This was first demonstrated using
tetrameric forms of MHC–peptide, bound together using
fluorescently labeled streptavidin.
►► Phenotypic
analysis
of
antigen-
specific
T
lymphocytes.368
From this work, the term ‘tetramer’ emerged as a
common name for these reagents. However, other
versions of peptide–MHC multimers have also been
made, with backbones other than streptavidin, and with
differing resulting valencies. The timeline of development of various MHC multimer reagents is reviewed
here.
►► Interrogating the repertoire: broadening the scope of
peptide-MHC multimer analysis.369
More recent efforts have focused on the parallel use of
many different MHC–peptide multimers, which is facilitated by combinatorial staining of each multimer species
using a different ‘barcode’ or combination of fluorescent
labels.
►► Simultaneous detection of many T-
cell specificities
using combinatorial tetramer staining.370
►► Parallel detection of antigen-specific T-cell responses
by multidimensional encoding of MHC multimers.371
Such parallelization has also been accomplished using
heavy metal-tagged tetramers and mass cytometry.
►► Combinatorial tetramer staining and mass cytometry analysis facilitate T-
cell epitope mapping and
characterization.372
►► Multiplexed peptide-
MHC tetramer staining with
mass cytometry.373
Application of barcoded tetramers, along with nanoparticle display to increase avidity, has been applied to
the tracking of neoantigen-specific T cells in tumors and
blood.
►► Sensitive detection and analysis of neoantigen-specific
T cell populations from tumors and blood.374
To create many different MHC–peptide multimers for
a given MHC protein, one can use a peptide-exchange
approach. With this method, a single MHC protein is
produced with an invariant peptide in its binding groove.
This is then exchanged for any peptide of interest, as
described here.
375
►► Design and use of conditional MHC class I ligands.
Arrays of MHC–peptide multimers can be used to
screen heterogeneous T cell populations for binding.
This provides a way to determine the specificities of T
cells for neoantigens, for example.
►► High throughput determination of the antigen specificities of T cell receptors in single cells.376
Conclusions
The use of MHC–peptide multimers to identify T cell
specificities is limited by the fact that each multimer

reagent identifies T cells specific for a single epitope
in the context of a single MHC allele. Historically, this
has restricted their use in tumor immune monitoring to
settings such as peptide vaccination, where the patient’s
human leukocyte antigen (HLA) type is selected, and
there is only one or a few specificities of interest. More
recently, the specificity limitation has been partly overcome by the use of many multimer reagents in parallel;
these reagents can be barcoded with unique combinations
of fluorescent or mass labels, to minimize the number of
detection channels required. The production of many
multimers using the same MHC protein is in turn facilitated by a peptide exchange manufacturing approach.
Once created, an array of peptide–MHC multimers can
be used to efficiently screen patient T cells for their specificity to different neoantigen epitopes.
Phospho-flow
The use of antibodies to specific phosphoepitopes, in
combination with flow cytometry phenotyping, was
pioneered in the lab of Garry Nolan, and has been called
‘phospho-flow’. The earliest papers from the Nolan lab
described the use of this technique to profile intracellular
signaling in either immune or cancer cells.
►► Intracellular phospho-
protein staining techniques
for flow cytometry: monitoring single cell signaling
events.377
►► Single cell profiling of potentiated phospho-protein
networks in cancer cells.378
►► Multiparameter analysis of intracellular phosphoepitopes in immunophenotyped cell populations by
flow cytometry.379
Conclusions
flow
Identification of signaling anomalies by phospho-
can be useful for probing both tumor and immune cells.
See the ‘Mass cytometry’ section for recent studies using
CyTOF-
based phospho-
flow to distinguish outcome
groups in acute myeloid leukemia based on signaling
properties.
AbSeq/CITE-seq
In order to analyze the binding of many antibody specificities in parallel on single cells, high-
throughput
based approaches have been developed.
sequencing-
These methods use nucleic acid-tagged antibodies and
barcoding of single cells with indexing beads, which
capture the nucleic acid tags from each cell for high-
throughput sequencing. This approach, dubbed AbSeq
(antibody-
based sequencing), was first published in
2017.
►► Abseq: Ultrahigh-
throughput single cell protein
profiling with droplet microfluidic barcoding.380
It is possible to combine AbSeq with transcriptomic
profiling, a method termed cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) or RNA
expression and protein sequencing (REAP-seq).
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Simultaneous epitope and transcriptome measurement in single cells.381
►► Multiplexed quantification of proteins and transcripts
in single cells.382
A protocol for performing such combined proteomic
and transcriptomic profiling on a microchip-based single-
cell genomics platform has been recently published.
►► Protein- and sequencing-
based massively parallel
single-cell approaches to gene expression profiling.383
►►

Conclusions
AbSeq has the potential to profile many more antibody
specificities in parallel than either fluorescence or mass
cytometry. In theory, the number of antibodies used is
limited only by cross-blocking of epitopes. However, it is
still an expensive method, and is generally performed on
a few thousand, but not millions, of cells per sample. It is
also not well suited to the study of intracellular proteins,
because fixation interferes with the ability to sequence the
nucleic acid tags. Combining AbSeq with transcriptomic
analysis, for example, CITE-seq, provides a novel way to
assess both RNA and protein expression in a highly multiplexed manner on single cells. It may be especially well
suited to extracting maximal information about immune
cells infiltrating a tumor.
Real-time functional assays
The xCELLigence technology (Acea Biosciences) has
been developed for cell-based electric impedance assays
to monitor and quantify cell proliferation, toxicity, and
morphology changes. This platform allows the monitoring of changes in the behavior and adhesion properties of cells through the measurement of impedance,
using gold-plated base biosensors in the bottom of culture
wells. Cellular status is monitored by label-free and real-
time automated reading.
This application can assess cell viability perturbations and determine either cell toxicity and cell death
or modification of cell proliferation on treatment with
compounds or drugs. Its real-time acquisition of data is
suitable to identify the optimal timepoints for a defined
cellular activity and to understand the related mechanisms. The xCELLigence technology has increasingly
been applied to immunotherapy in order to better
understand the complex interaction of immune cells with
tumor cells and to verify the efficacy of different immunotherapy approaches or their combinations. Examples are
the treatment of cells with either biological agents (eg,
agonist or antagonist monoclonal antibodies, or bispecific T cell engagers) or through coculture with effector
cells (eg, T, NK, or CAR T cells).
►► xCELLigence system for real-
time label-
free monitoring of growth and viability of cell lines from hematological malignancies.384
►► Application of real-time cell electronic analysis system
in modern pharmaceutical evaluation and analysis.385
►► In vitro immunotherapy potency assays using real-
time cell analysis.386
30

►►

Avidity characterization of genetically engineered
T-cells with novel and established approaches.387

Conclusions
The xCELLigence platform can provide real-time quantitative determination of functional changes in cells,
providing highly reproducible results with a simple workflow. It represents a useful tool to investigate and monitor
the mechanisms of action of immunotherapy approaches.
This method allows the monitoring of the functional
properties of immune cells and other biological drugs,
although no extensive results are available regarding its
usage to either predict or correlate with the in vivo activity
of these therapeutic tools. The combination of xCELLigence with highly dimensional immune phenotype
profiling is warranted to achieve deep characterization
of immune responses associated with immunotherapy
interventions.
Proteomic biomarkers discovery: target identification and
immunomonitoring
Minimum residual disease detection
Highly sensitive, standardized techniques are necessary
for the detection of minimal residual disease (MRD)
in order to assess therapy responses and provide more
accurate prognoses, leading to improved personalized
treatments. Molecular techniques, such as allele-specific
oligonucleotide quantitative PCR (ASO-qPCR), represent
the traditional approaches.
►► High applicability of ASO-
RQPCR for detection of
minimal residual disease in multiple myeloma by
entirely patient-specific primers/probes.388
A major drawback of ASO-qPCR, namely the necessity
of using patient-specific probes for B cell malignancies
exhibiting somatic hypermutation (eg, multiple myeloma
(MM)), is overcome by NGS (also known as deep
sequencing or high-throughput sequencing) of immunoglobulin genes.
►► Prognostic value of deep sequencing method for
minimal residual disease detection in multiple
myeloma.389
►► A clinical perspective on immunoglobulin heavy
chain clonal heterogeneity in B cell acute lymphoblastic leukemia.390
Flow cytometry classically provided lower sensitivity
than molecular techniques. However, next-
generation
flow cytometry (NGF) approaches reach sensitivities
comparable with molecular methods, and have the advantage of faster turnaround times, broader applicability,
and lower cost.
►► Next generation flow for highly sensitive and standardized detection of minimal residual disease in
multiple myeloma.391
►► ClonoSEQ assay for the detection of lymphoid
malignancies.392
While MRD detection is an established tool in the
management of hematological malignancies, highly
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sensitive liquid biopsy assays for the assessment of disseminated tumor cells in the context of solid tumors have been
developed more recently. These probe for CTCs or circulating tumor-derived factors such as ctDNA, as for example,
Natera’s Signatera assay, which provides early disease recurrence prediction based on ctDNA. Since CTCs are rare
events, marker-dependent (such as Menarini’s DEPArray)
or marker-
independent techniques (eg, microfiltration)
are applied to enrich them prior to downstream analysis.
►► Analysis of plasma cell-
free DNA by ultradeep
sequencing in patients with stages I to III colorectal
cancer.393
►► Liquid biopsy and minimal residual disease – latest
advances and implications for cure.394
These techniques as well as additional techniques such
as droplet digital PCR (ddPCR), positron emission tomography (PET)-
CT, PET-
MRI, CyTOF, and monoclonal
immunoglobulin rapid accurate mass measurement
(miRAMM) are being explored as complementary or
alternative approaches for MRD assessment as discussed
here.
►► Droplet digital PCR for minimal residual disease
detection in mature lymphoproliferative disorders.395
►► Minimal residual disease in multiple myeloma:
impact on response assessment, prognosis and tumor
heterogeneity.396
Conclusions
Detection and monitoring of MRD play an important role
in the management of patients with hematological malignancies. The somatic hypermutation seen in MM means
that many molecular approaches, although exhibiting
high sensitivities, are not applicable to all patients, and
that false-negatives remain a challenge. With the advent
of standardized NGF that is applicable to all patients and
reaches comparable sensitivities with molecular techniques, turnaround times and costs are vastly reduced.
All of these assays rely on blood or bone marrow samples
and are therefore prone to sampling errors, as they
ignore spatial heterogeneity in clones. Complementing
molecular or flow cytometry-based assays with imaging
techniques will enrich MRD readouts, improving clinical
follow-up. Highly sensitive techniques are also starting to
be harnessed for the detection of tumor-derived material
or single tumor cells disseminated from primary solid
tumor lesions in liquid biopsies.
Neoantigens
Neoantigens are potentially immunogenic epitopes that
are created by tumor mutations or chromosomal rearrangements in the course of an individual’s cancer development.
They have emerged as an important target of antitumor
T cells, and this reactivity may be important both in the
context of ICIs as well as adoptive cell therapy (ACT).
Detection of neoantigens and neoantigen-specific T cells
Robbins PF et al397 described a method to identify mutated
proteins in patient tumors that may be targets of antitumor

T cell immunity using whole-exome sequencing data and
MHC binding algorithms.
►► Mining exomic sequencing data to identify mutated
antigens recognized by adoptively transferred tumor-
reactive T cells.397
In a study by Linnemann C et al,398 autologous immortalized B lymphoblastoid cell lines and in silico prediction models are used to demonstrate recognition of
neoepitopes by CD4+ T cells.
►► High-
throughput epitope discovery reveals frequent
recognition of neo-antigens by CD4+ T cells in human
melanoma.398
As mentioned in the ‘Multimers’ section, stable
tetramers can be synthesized using ultraviolet-mediated
peptide exchange. This method has been applied to identify neoantigen-specific T cells.
►► Generation of peptide MHC class I complexes
through UV mediated ligand exchange.399
Various methods have been used to screen for the
targets of TCRs identified in tumor tissues or other
settings. These include screening of yeast display libraries
bearing peptide-human leukocyte antigen (pHLA), lentiviral delivery of antigen libraries for display by HLA, identification of pHLA that appropriate TCRs from T cells via
trogocytosis, and use of signaling and antigen-presenting
bifunctional receptors.
►► Antigen identification for orphan T cell receptors
expressed on tumor-infiltrating lymphocytes.400
►► T-
Scan: a genome-
wide method for the systematic
discovery of T cell epitopes.401
402
►► T cell antigen discovery via trogocytosis.
►► T cell antigen discovery via signaling and antigen-
presenting bifunctional receptors.403
Another approach uses tetramer-
associated TCR-
seq
to link TCR sequences to their cognate antigen in single
cells. This approach has the potential advantage of high-
throughput evaluation of antigen specificities.
►► High throughput determination of the antigen specificities of T cell receptors in single cells.376
The evolving dynamic of tumor targeting by neoantigen-
specific T cells and resulting escape of tumor cells lacking
the neoantigen(s) contributes to ‘immunoediting’,
described in this seminal publication.
►► Neoantigen landscape dynamics during human melanoma-T cell interactions.404
In view of the complexity of cancer genomes, there is
a need to explore unbiased approaches to identify the
full range of immunogenic peptides presented by tumors
(the ‘immunopeptidome’). These strategies have typically relied on mass spectrometry, immunoprecipitation,
or peptide elution, for example.
►► Predicting
immunogenic
tumour
mutations
by combining mass spectrometry and exome
sequencing.405
In this approach, whole exome and transcriptome
data were combined with mass spectrometry and in silico
methods to identify immunogenic mutations.
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Antigen presentation profiling reveals recognition of
lymphoma immunoglobulin neoantigens.406
Another strategy combined exome sequencing with
MHC isolation and peptide identification to uncover
tumor neoantigens from ovarian carcinoma cell lines.
►► The immunopeptidomic landscape of ovarian
carcinomas.407
This approach uses chemical methods followed by mass
spectrometry analysis to identify HLA binding peptides
from direct analysis of tumor cells. Candidate antigens
are then validated with complementary methods.
►► HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia
immune responses in chronic lymphocytic leukemia
(CLL).408
►►

Conclusions
Strategies for unbiased identification of HLA-
binding
and/or immunogenic peptides from tumor cells have
the potential to provide targets for novel vaccine strategies. These have also led to the identification of both
mutated as well as non-mutated peptides as targets for
immunotherapy.
Role of neoantigens in immunotherapy
Please refer to the TMB section for the role of neoantigens in the response to ICIs. In addition, unique or
shared neoantigen-directed, genetically engineered cells
have been used as a cellular immunotherapy and have led
to regression of tumors.
►► Cancer immunotherapy based on mutation-
specific
CD4+ T cells in a patient with epithelial cancer.409
►► T-
cell transfer therapy targeting mutant KRAS in
cancer.410
►► Mutated nucleophosmin 1 as immunotherapy target
in acute myeloid leukemia.411
►► Neoantigen screening identifies broad TP53
mutant immunogenicity in patients with epithelial
cancers.412
Conclusions
In view of the growing importance of neoantigen-specific
T cells in tumor immunity, several approaches to identify
and expand these cells have been developed. These strategies also demonstrate the feasibility of harnessing these
T cells for cancer therapy.
Proliferation and cytotoxicity assays
Ex vivo or in vitro cell proliferation can be determined by
multiple technologies. The earliest approach is to label
cells with [3H]-thymidine and quantify proliferation by
a gamma counter, which corresponds to DNA synthesis,
and has been used to monitor ex vivo immune responses
to cancer vaccines. Bromodeoxyuridine (BrdU) incorporation assays use absorbance as the readout and avoid
radiolabeled dyes. Other cell proliferation assays use dyes
that measure the metabolic activity of cells (eg, MTT
(using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazol
32

ium bromide), WST-1 (using water-soluble tetrazolium
salts)) by permeabilizing the cells and reacting with
enzymes or other metabolic factors.
►► Assays for monitoring cellular immune responses to
active immunotherapy of cancer.413
►► Immunotherapy of metastatic malignant melanoma
by a vaccine consisting of autologous interleukin2-
transfected cancer cells: outcome of a Phase I
study.414
►► Generation of immunity to the HER-2/neu oncogenic
protein in patients with breast and ovarian cancer
using a peptide-based vaccine.415
Fluorescent dyes can be used to monitor cell populations with different rates of division and proliferation. Carboxyfluorescein succinimidyl ester (CFSE) has
been commonly used to assess lymphocyte division and
proliferation by flow cytometry. CFSE can covalently
label intracellular molecules, and CFSE concentration is proportionally diluted in cell progeny according
to the number of subsequent cell divisions. DELFIA
enhanced lanthanide fluorescence immu(dissociation-
noassay) is based on the measurement of time-resolved
fluorescence intensity. These fluorescence-
based dyes
are compatible with multiparametric staining with other
fluorochromes.
►► The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte
proliferation.416
+
+
+
►► Role of STAT3 in CD4 CD25 FOXP3 regulatory
lymphocyte generation: implications in graft-versus-
host disease and antitumor immunity.417
The efficiency of in vitro expansion of T cells engineered to express exogenous antigen-
specific CAR or
TCR measured by proliferation assays can represent a
relevant parameter and a surrogate marker of possible in
vivo persistence.
►► Adoptive cell transfer therapy following non-
myeloablative but lymphodepleting chemotherapy
for the treatment of patients with refractory metastatic melanoma.418
419
►► CAR T cell immunotherapy for human cancer.
420
►► CARs on track in the clinic.
Cytotoxicity assays measure cell death induced by cytotoxic stimuli, environmental changes, or cell-
mediated
killing. They are based on cell membrane integrity,
using vital dyes that allow the exclusion of viable cells,
or assessing the release of markers from dying cells (eg,
CFSE). In addition, metabolic activity measurements, for
example, MTT, lactate dehydrogenase (LDH), or ATP
assays, are also used to measure cell viability. A reliable
cell-mediated cytotoxicity assay based on radiolabeled 51Cr
release has been substituted by the development of the
assays mentioned above. DELFIA also represents a reliable
and simple technology to asses either antibody-dependent
cell-mediated cytotoxicity (ADCC) or cell-mediated cytotoxic assays. These assays have been applied to the functional characterization of antitumor and antigen-specific
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T and NK cell responses, highlighting relevant therapeutic
implications.
►► Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional 51CR
release assay.421
►► WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for
adoptive immunotherapy after allogeneic stem cell
transplantation.422
►► Preparation of cytokine-activated NK cells for use in
adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential.423
Conclusions
Cell proliferation and cytotoxic assays can monitor
cell-mediated immunity in patients with cancer. Critical considerations include selection of target cells
and baseline controls for the assays, and the limitations in applying these techniques to high-throughput
screening studies. Nevertheless, in specific cases, for
example, characterization of cell-mediated antitumor
responses, the integration of cytokine release determination with proliferation and cytotoxic assays should be
considered.
Assessment of ex vivo antigen-specific immune responses
TAAs are recognized by T cells in the form of MHC/
peptide complexes. The discovery and molecular characterization of TAAs allowed the identification and categorization of three main types of antigens.
1. Differentiation antigens that are specific to the cellular lineage. These antigens are overexpressed by tumor
cells but also shared with normal tissue (eg, carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (Ep-CAM), mucin-1 (MUC-1), melanoma antigen
recognized by T cells-1 (MART-1/Melan-A), glycoprotein 100 (gp100), and tyrosinase (Tyr)).
2. Cancer-
Testis (CT) antigens (eg, MAGE, GAGE,
LAGE, and NY-ESO-1) are expressed in tumors with
different histological origins and their expression in
normal tissues is limited to testicular germ cells and
placenta.
3. Mutated antigens or neoantigens derived from non-
synonymous somatic mutations. These TAAs are not
expressed by normal cells and display superior immunogenic potency as compared with differentiation/self
or CT antigens. Details of these TAAs have been provided above.
Single or multiple peptides derived from the TAAs
mentioned above have been administered in the context
of phase I/II clinical studies for vaccination of patients
with different types of tumors. However, cancer vaccines
have not been associated with durable clinical responses
in patients with cancer, possibly as a result of low immunogenic potency and the pre-existence in patients’ body
of tolerogenic/anergic T cells specific for these TAAs.
Nevertheless, antigen-specific T cell responses could be

detected in the circulation of up to 50% of patients with
cancer undergoing vaccination. Of note, antigen-specific
T cell responses in the circulation of patients with cancer
could be detected ex vivo with, in some cases, association
with their clinical outcome.
►► Progress in the development of immunotherapy for
the treatment of patients with cancer424
425
►► Cancer/testis antigens, gametogenesis and cancer.
►► Therapeutic vaccines for cancer: an overview of clinical trials.426
The monitoring of circulating antigen-specific T cell
responses in patients with cancer can be performed by
ex vivo coculture of peripheral blood lymphocytes with
either peptides containing TAA-derived epitopes or HLA-
matched antigen-presenting cells loaded with peptides.
Cytokine release assays, such as ELISA, ELISPOT, or
intracellular staining by flow cytometry, have been used
as readouts of antigen-specific reactivity by T cells. These
methods have been described above. The majority of
studies assessed the effector functions of antigen-specific
T cells by measuring the release of IFN-γ, but in some
cases also analyzed the multifunctional properties of
T cells by assessing the release of multiple cytokines.
Multimer staining in combination with flow cytometry
has been used to determine the antigen-specific reactivity
of T cells.
►► Flow cytometric determination of intracellular or
secreted IFNgamma for the quantification of antigen
reactive T cells.427
►► Immunologic monitoring of cancer vaccine trials
using the ELISPOT assay.428
►► MHC class II tetramer analyses in AE37-
vaccinated
prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4+ T-cells.429
►► Anti-
CTLA-4 antibody therapy: immune monitoring during clinical development of a novel
immunotherapy.430
Cancer vaccine studies based on the usage of neoantigens as a source of immunization also showed both the
expansion of pre-existing T cell responses and the induction of new T cells reactive against this type of antigen in
patients with objective clinical responses.
The ex vivo assessment of antigen-
specific reactivity, including neoantigens, could also be successfully
performed for TILs, and represented the rationale for
ACT protocols for patients with solid tumors (eg, melanoma, CRC, and breast cancer). The efficient recognition by TILs of mutated antigens expressed by autologous
tumor cells has been associated with tumor regressions
following ACT.
►► Somatically mutated tumor antigens in the quest for a
more efficacious patient-oriented immunotherapy of
cancer.431
►► Exploiting the curative potential of adoptive T-
cell
therapy for cancer.432
►► Tumor exome analysis reveals neoantigen-
specific
T-
cell reactivity in an ipilimumab-
responsive
melanoma.120
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Conclusions
Ex vivo TAA-specific T cells can be detected in patients with
cancer, either as naturally occurring immune responses
or as a result of therapeutic interventions through cancer
vaccines or immune checkpoint blockade. In some cases,
the detection of antigen-specific T cells in the circulation
or at the tumor site could be associated with patients’
clinical outcome, and might represent a biomarker for
clinical responses to immunotherapy. However, this methodology requires the knowledge of a patient’s HLA type,
the availability of sufficient TAA-specific TILs at the tumor
site, and the identification and immunogenic validation
of HLA-restricted TAA-derived epitopes, and cannot be
performed in a high-throughput manner. Development
of methods that allow large-scale investigations and standardization is warranted for high-
throughput ex vivo
assessment of antigen-specific T cell responses.
Immune contexture biomarker discovery
Multiplex immunofluorescent staining
Tissue IHC, a century-old technology, has undergone a
major technological revolution in recent years. With the
advancement of three major components, (1) biomarker
staining methods, (2) whole slide imaging (WSI) techniques, and (3) image analysis software, multiplexing
technologies are slowly replacing conventional single-
plex IHC assays. Tissue multiplexing technologies play a
vital role in understanding the complex TME in cancer
immunotherapy. Staining multiple protein biomarkers
on a single tissue section facilitates an understanding
of complex cell–cell interactions, cell migration and
infiltration of immune cells, and cellular distance and
density.
Staining methods
Three different staining methods are gaining popularity:
(1) chromogenic multiplexing, (2) fluorescent multiplexing, and (3) mass spectrometry.
Chromogenic multiplexing
Duplex IHC assay: The clinical significance of locating
two immune populations (CD3+ and CD8+) in and
around a tumor initiated the concept of Immunoscore,
the first validated immune-based assay from FFPE tissue
for cancer classification. This standardized assay from
HalioDx stains two sequential sections with CD3+ and
CD8+, respectively, scans the slides, and digitally coregisters the markers.
►► Biomarkers immune monitoring technology primer:
Immunoscore Colon.21
The Halioseek assay from HalioDx identifies PD-
L1
expression and CD8+ populations in the TME from a
single slide to help define treatment options for patients
with NSCLC. Halioseek is currently a CE-IVD assay (in
vitro diagnostic assay certified in the European Economic
Area).
In a research setting, a chromogenic multiplex method
evaluating 12 biomarkers simultaneously on single FFPE
34

sections of 38 SCCHN cases was used for comprehensive
immune phenotyping:
►► Quantitative multiplex immunohistochemistry reveals
myeloid inflamed tumor-immune complexity associated with poor prognosis.433
The availability of new chromogenic dyes of vivid colors
is opening up new possibilities for the chromogenic
multiplexing field. New series of chromogenic detection
kits from Roche (DISCOVERY Teal, DISCOVERY Purple,
DISCOVERY Yellow) and Biocare Medical (Viva Green,
Bajoran Purple, Ferangi Blue) are entering multiplexing
research.
►► Covalently deposited dyes: a new chromogen paradigm that facilitates analysis of multiple biomarkers
in situ.434
►► Chromogenic
multiplex immunohistochemistry
reveals modulation of the immune microenvironment associated with survival in elderly patients with
lung adenocarcinoma.435
Conclusions
Duplex chromogenic assays involving a simple workflow
are rapidly entering the clinic to support cancer immunotherapy. However, to develop higher order chromogenic multiplexing assays with a panel of coexpressing
biomarkers, advancements in chromogenic dye chemistry, automated stainers, whole slide scanners, and
sophisticated image analysis software are necessary and
are currently being developed.
Fluorescent multiplexing
Multiplex immunofluorescent staining technology allows
multiple biomarkers tagged with distinct fluorescent dyes
to be interrogated separately or in combination, and has
exhibited exponential growth in recent years. Although
fluorescent multiplex assays are predominantly research
use only or lab-derived test, future clinical adoption is
anticipated. The technology requires investment in fluorescent microscopes and scanners, and relies heavily on
image analysis software for downstream analysis and effective outcomes.
This section highlights three different fluorescent
staining methodologies:
Simultaneous multiplexing
The simultaneous multiplexing staining method involves
the application of a cocktail of primary and secondary
antibodies to the tissue, thereby simplifying the staining
process and saving time.
The UltraPlex staining technology from Cell IDx can
detect four to six biomarkers in a single tissue section
using a simultaneous multiplexing method. The staining
assay uses the standard two-step staining process where
cocktails of primary and secondary antibodies are used.
Each primary antibody is conjugated to a unique modified hapten and each hapten-specific secondary antibody
is labeled with a distinct fluorescent dye.
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Hapten-
anti-
hapten technique for two-
color IHC
detection of phosphorylated EGFR and H2AX
using primary antibodies raised in the same host
species.436
The InSituPlex staining technology from Ultivue
involves the repeated application of antibody cocktails
(up to four antibodies per round of staining) labeled
with unique DNA barcodes to a tissue section, which,
following an amplification step, are detected by hybridization with complementary DNA barcodes tagged with
distinct fluorophores.
►► DNA barcoded labeling probes for highly multiplex
Exchange-PAINT imaging.437
The CODEX (CO-
Detection by indEXing) staining
technology from AKOYA Biotechnology enables higher
orders of multiplexing (39-plex) on a single tissue section.
Here, the primary antibodies are conjugated to proprietary barcodes, each with its unique oligonucleotide
sequence. The dye-labeled reporter targets the barcode
with high specificity. Although the primary antibody
staining is a single step, signals are detected by sequential
scanning and imaging of three fluorescent reporters in
each round.
►► Deep profiling of mouse splenic architecture with
CODEX multiplexed imaging.438
Morphology-driven higher order multiplexing of the
tumor inflammation signature that simultaneously measures DNA, RNA, and protein using GeoMax DSP technology is available from NanoString.
►► New tools for pathology: a user’s review of a highly
multiplexed method for in situ analysis of protein and
RNA expression in tissue.439
►►

Sequential multiplexing
The sequential multiplex-
staining method involves
multiple (5 to 8) biomarker detection on a single tissue
section. The most commonly used method consists of
staining with unmodified primary antibody and horseradish peroxidase-
conjugated secondary antibody
followed by enzyme-
mediated deposition of tyramide-
fluorophores on the epitope of interest. A heat deactivation step is applied between each staining round.
Recent adoption of these staining protocols to automated
staining platforms (DISCOVERY ULTRA from Roche,
BOND RX from Leica Biosystems) has reduced the
staining time significantly. Two commonly used sequential multiplexing staining methods are described here:
►► Fully automated 5-
plex fluorescent immunohistochemistry with tyramide signal amplification and
same species antibodies.440
►► An automated staining protocol for seven-
color
immunofluorescence of human tissue sections for
diagnostic and prognostic use.441
Cyclic multiplexing technology
The cyclic multiplexing technology MultiOmyx from
NeoGenomics (originally developed by GE Global
Research) is capable of higher order multiplexing of

up to 60 biomarkers on a single tissue section. Each
staining/detection round involves tissue incubation
with a cocktail of two to four primary antibodies directly
conjugated to unique fluorescent dyes, followed by tissue
imaging, chemical deactivation of the fluorescent dyes,
and rescanning to capture the background image. This
technology requires dedicated scanners and image analysis platforms.
►► Highly multiplexed single-
cell analysis of formalin-
fixed, paraffin-embedded cancer tissue.442
Mass spectrometry for tissue multiplexing
Mass spectrometry is used for identifying multiple
biomarkers from a single tissue section. Typically, the
tissue section is incubated with a cocktail of antibodies
tagged with unique metal tags, each targeting a different
protein of interest. Such methodologies are supported by
dedicated imaging systems and image analysis software.
Two technologies available in the market are highlighted
here.
Imaging mass cytometry (IMC)
Fluidigm has combined mass cytometry or CyTOF with
the Hyperion Imaging System to perform multiplexing
on tissue sections. IMC on the Hyperion Imaging System
enables simultaneous analysis of 4–37 protein markers
from a single tissue scan. The process, however, leads
to vaporization of the biological material during the
scan.
►► histoCAT: analysis of cell phenotypes and interactions
in multiplex image cytometry data.443
Multiplexed ion beam imaging (MIBI) technology
The MIBI technology from IONpath uses a cocktail of
antibodies, each tagged to different lanthanides for tissue
staining. The ion beam imaging scope (MIBIscope can
identify up to 40+ markers simultaneously from the tissue.
The sample undergoes raster scanning with an ion beam
that allows multiple rescannings of the tissue at different
resolutions.
►► Structured tumor-
immune microenvironment in
triple negative breast cancer revealed by multiplexed
ion beam imaging.444
Conclusions
Multiple multiplexing methods are available to identify up to hundreds of biomarkers from a single tissue
section. However, most of these technologies are
extensively used in biomarker exploratory studies for
cancer immunotherapy. Over time, the immunotherapy
community may adopt a few key technologies for clinical
practice.
Whole slide imaging and image analysis
Whole slide scanners
Although various multiplexing staining techniques are
currently available, the staining outcome is heavily dependent on scanning platforms and downstream analysis
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software. In the field of immunotherapy, the general
consensus is leaning toward WSI, as it is more informative than a selected number of regions of interest (ROIs)
from a stained tissue section. However, WSI is limited by
throughput and remains one of the key bottlenecks in the
turnaround time of the workflow.
Some tissue multiplexing technologies provide complementary scanners along with an image analysis platform
such as CODEX from AKOYA Biosciences, MultiOmyx
from NeoGenomics, and mass spectrometry multiplexing
from Fluidigm and IONpath.
Multi-
filter-
based fluorescent whole slide scanners
currently available in the market include the Zeiss Axio
Scan Z1, NanoZoomer series from Hamamatsu, Aperio
VERSA from Leica Biosystems, Olympus V120, and so
on. The Vectra and Polaris scanner series from Phenoptics (AKOYA Biosciences) have additional multispectral
imaging capabilities. These research instruments are
capable of performing both bright field and fluorescent
WSI scans.
Philips IntelliSite Pathology Solution is the first WSI
system approved (in 2017) by the FDA for primary diagnosis in surgical pathology. Some of the key players in
the space are Roche, Leica Biosystems, 3DHistech, and
Hamamatsu. Clinical implications and the future of WSI
are discussed in the following paper.
►► US Food and Drug administrative approval of whole
slide scan for primary diagnosis: a key milestone is
reached or new questions are raised.445
Image analysis platforms
Various image analysis software systems are tailored for
analyzing multiplex slides. Indica Lab’s HALO contains
a multiplex IHC module for chromogenic multiplex
and a Highplex FL module for fluorescent multiplex
image analysis. Visiopharm offers the Phenomap multiplexing image analysis software, while Phenoptics’
inForm image analysis software is another commonly
used tool. Some additional analysis platforms are AQUAnalysis from HistoRx, MultiOmyx from NeoGenomics,
HistoQuant from 3DHistech, and Tissue Studio from
Definiens.
With the advent of artificial intelligence (AI) in the
digital pathology space, rapid developments are anticipated. The challenges and opportunities of the field have
been described in the following review articles.
►► Artificial intelligence and digital pathology: Challenges and opportunities.446
►► Artificial intelligence in digital pathology—new tools
for diagnosis and precision oncology.447
Conclusions
The availability of new tools and technologies is opening
up new options for WSI and image analysis. However,
major improvements are required in workflow scalability,
high-
throughput scanners, ease of use protocols, scan
turnaround time, high-quality image capture, and rapid
image analysis algorithms. Computer vision and AI may
36

transform the digital pathology landscape in the next few
years.
Application of tissue multiplexing technology
Different groups have successfully applied the complex
multiplexing workflow to answer key questions in the
field of cancer immunotherapy. The following are some
of the recent publications.
►► Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis.448
►► Validation of multiplex immunofluorescence panels
using multispectral microscopy for immune-profiling
of formalin-
fixed and paraffin-
embedded human
tumor tissues.449
►► Multispectral fluorescence imaging allows for
distinctive topographic assessment and subclassification of tumor-infiltrating and surrounding immune
cells.450
►► Multiplex immunohistochemistry for molecular and
immune profiling in lung cancer-just about ready for
prime time?451
A comprehensive review of complex tissue multiplexing
technology is provided here.
►► State-
of-
the-
art of profiling immune contexture in
the era of multiplexed staining and digital analysis to
study paraffin tumor tissues.452
Conclusions
Tissue multiplexing technology holds promise for clinical adoption. Chromogenic duplex assays, a whole slide
scanner, and digital pathology algorithms have obtained
clinical approval in recent years. Maturation of this field
will provide enormous benefits for the field of cancer
immunotherapy.
Software and tools for data analysis
Gene expression analysis tools
Data analyses of gene expression profiling can be categorized depending on the study objectives, that is, class
discovery, class comparison, class prediction, and survival
analysis.
►► Design
and
analysis
of
DNA
microarray
investigations.453
Class discovery is an unsupervised method with the goal
of discovering clusters among specimens or among genes.
Hierarchical clustering algorithms, principal component
analysis, a self-organizing map, and non-negative matrix
factorization are popular methods to find clusters of
samples or genes.
►► Cluster analysis and display of genome-
wide expression patterns.454
►► Principal
components analysis to summarize
microarray experiments: application to sporulation
time series.455
►► Analysis of gene expression data using self-organizing
maps.456
►► Knowledge-
based gene expression classification via
matrix factorization.457
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Class comparison aims to identify genes differentially
expressed between two or more different tissue types or
experimental conditions. For microarray gene expression data, a Student’s t-test is generally used to identify significantly differentially expressed genes between
two phenotype classes, assuming the log-transformed
ratio or intensity data are approximately normally
distributed. A multiple testing problem occurs during
class comparison due to the simultaneous testing of all
genes. The false discovery rate method is commonly
used to control for false discoveries in a set of identified genes.
►► Microarrays, empirical Bayes methods, and false
discovery rates.458
►► Significance analysis of microarrays applied to transcriptional responses to ionizing radiation.459
►► Controlling the false discovery rate: a practical and
powerful approach to multiple testing.460
Class prediction is used to predict the phenotype
of new samples from their gene expression. Popular
prediction methods include diagonal linear discriminant analysis, K-
nearest neighbors, support vector
machine, and random forest. Lasso and least angle
regression (LARS) can be used to build prediction
models with continuous outcomes. Cross validation
needs to be properly performed to avoid overfitting,
and the final model always needs to be evaluated on
independent data sets.
►► Regularized linear discriminant analysis and its application in microarrays.461
►► Diagnosis of multiple cancer types by shrunken
centroids of gene expression.462
►► Gene selection for sample classification based on
gene expression data: study of sensitivity to choice of
parameters of the GA/KNN method.463
►► Knowledge-based analysis of microarray gene expression data by using support vector machines.464
►► Gene selection and classification of microarray data
using random forest.465
►► The elements of statistical learning: data mining,
inference, and prediction (Springer Series in
Statistics).466
►► The lasso method for variable selection in the Cox
model.467
►► A paradigm for class prediction using gene expression
profiles.468
Gene expression-
based survival analyses address two
major areas: (1) identifying signatures that are associated with survival, and (2) building a prognostic and/
or predictive model based on survival data. One method
uses a Cox proportional hazards model to relate survival
time to k ‘supergene’ expression groups. The ‘supergene’
expression levels are the first k principal component, that
is, linear combinations of expression levels of the subset
of genes that are univariately correlated with survival.
Another method uses a penalized Cox regression model
to find genes related to survival, which can be done using
the R package glmnet.

Diagnostic and prognostic prediction using gene
expression profiles in high-
dimensional microarray
data.469
►► ‘Gene shaving’ as a method for identifying distinct
sets of genes with similar expression patterns.470
►► Regularization paths for Cox’s proportional hazards
model via coordinate descent.471
The R statistical programming language together
with the Bioconductor repository provides over 1000
packages for the analysis of high-throughput genomic
data including gene expression. For users with limited
or no programming skills, a more suitable choice may
be GEO2R, which can provide simple data analysis on
a curated National Center for Biotechnology Information (NCBI) GEO data set. Such users can also use a
general-purpose software that can handle more sophisticated data analyses. For example, BRB-ArrayTools is
a Windows desktop application with a graphical interface designed for use by researchers who want to use
state-of-the-art statistical methods for gene expression
analysis.
►► Bioinformatics and computational biology solutions
using R and Bioconductor.472
►► GEOquery: a bridge between the Gene Expression
Omnibus (GEO) and BioConductor.473
►► Analysis
of
gene
expression
data
using
BRB-ArrayTools.474
►►

WES and RNA-seq data analysis tools
The first step in the workflow of WES/RNA-
seq data
is mapping. Raw sequence data are commonly saved
in the FASTQ format, which needs to be mapped to a
reference genome by using an alignment algorithm.
Popular mapping/alignment tools include Burrows-
Wheeler Aligner (BWA)-Maximal Exact Match (MEM)
and Subread for DNA-seq data, and TopHat2 and spliced
transcripts alignment to a reference (STAR) for RNA-seq
data.
►► TopHat2: accurate alignment of transcriptomes
in the presence of insertions, deletions and gene
fusions.475
476
►► STAR: ultrafast universal RNA-seq aligner.
►► The Subread aligner: fast, accurate and scalable read
mapping by seed-and-vote.477
►► Aligning sequence reads, clone sequences and
assembly contigs with BWA-MEM.478
Next, variant calling can be conducted on both aligned
RNA-seq and DNA-seq data using Samtools or Genome
Analysis Toolkit best practices pipeline tools. For WES
data with tumor/normal pairs, somatic mutations are
called using tools such as MuTect (for SNPs) and Mutect2
(for indels). The variant call format files containing
variant information are finally annotated using tools such
as ANNOVAR, SnpEff, and variant effect predictor (VEP).
►► From FastQ data to high confidence variant calls: the
Genome Analysis Toolkit best practices pipeline.479
►► The
sequence alignment/map format and
SAMtools.480
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Sensitive detection of somatic point mutations in
impure and heterogeneous cancer samples.481
►► ANNOVAR: functional annotation of genetic variants
from high-throughput sequencing data.482
►► A program for annotating and predicting the effects
of single nucleotide polymorphisms, SnpEff: SNPs in
the genome of Drosophila melanogaster strain w1118;
iso-2; iso-3.483
484
►► The Ensembl variant effect predictor.
Further levels of analyses based on WES data include
using tools such as Sequenza to generate allele-specific
copy numbers from the mapped reads and PyClone to
generate the tumor clonal distribution. To get an estimate of tumor purity and ploidy, fraction and allele-
specific copy number estimates from tumor sequencing
(FACETS) can be applied on mapped reads. In addition,
PolySolver can be used to predict patient HLA types, and
the MSI status can be detected using a method called
microsatellite instability by NGS (mSINGS). Finally,
multiple pipelines have been developed to predict
neoantigens based on annotated variants in the translated protein sequence.
►► Sequenza: allele-specific copy number and mutation
profiles from tumor sequencing data.485
►► PyClone: statistical inference of clonal population
structure in cancer.486
►► FACETS: allele-
specific copy number and clonal
heterogeneity analysis tool for high-throughput DNA
sequencing.487
►► Comprehensive analysis of cancer-associated somatic
mutations in class I HLA genes.488
►► Microsatellite instability detection by next generation
sequencing.489
490
►► Applications of immunogenomics to cancer.
To generate quantitative measurements from the
aligned RNA-
sequence data, the high-
throughput
sequencing (HTSeq) method and featureCounts software can be applied to generate count data. Similar
tools include RNA-
seq by expectation maximization
(RSEM) and Salmon. Due to the nature of RNA-seq data,
differential expression analysis for sequence count data
(DESeq), DESeq2, Cuffdiff, and EdgeR use a negative
binomial distribution with generalized linear models
to determine the significance of genes that are differentially expressed between classes. The mapped reads
from RNA-seq data can be further explored to study the
immune repertoire of the TCR and B cell receptor using
tools such as TCR repertoire utilities for solid tissue/
tumor (TRUST), and to analyze immune cell composition using tools such as cell type identification by
estimating relative subsets of RNA transcripts (CIBERSORT) and the tumor immune estimation resource
(TIMER).
►► HTSeq-
a Python framework to work with high-
throughput sequencing data.491
►► featureCounts:
an
efficient
general-
purpose
program for assigning sequence reads to genomic
features.492

►►
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RSEM: accurate transcript quantification from RNA-
seq data with or without a reference genome.493
►► Salmon provides fast and bias-aware quantification of
transcript expression.494
►► Differential expression analysis for sequence count
data.495
►► Moderated estimation of fold change and dispersion
for RNA-seq data with DESeq2.496
►► edgeR: a Bioconductor package for differential
expression analysis of digital gene expression data.
Bioinformatics.497
►► Differential gene and transcript expression analysis of
RNA-seq experiments with TopHat and Cufflinks.498
►► Antigen receptor repertoire profiling from RNA-seq
data.499
►► Profiling tumor infiltrating immune cells with
CIBERSORT.500
►► Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.501
For scRNA-seq data, scalability and technical noise are
two main bioinformatics challenges. Certain methods
that were developed for bulk cell RNA-
seq cannot
be applied directly and require adaptation. Many
methods and tools have been developed specifically for
scRNA-seq data. For example, Scater, SCnorm, Seurat,
and SCANPY are R or Python packages developed
to facilitate rigorous preprocessing, quality control,
normalization, and visualization of scRNA-
seq data.
Depending on the experimental design, protocol, and
platform, SCONE uses a data-driven approach to allow
the user to select an appropriate normalization strategy
for scRNA-seq data. Falco is a cloud-based scRNA-seq
processing framework which provides a scalable and
efficient computational solution. For data visualization,
many tools, such as t-
distributed stochastic neighbor
embedding (t-SNE), uniform manifold approximation
and projection (UMAP), and single-cell interpretation
via multi-
kernel learning (SIMLR) can be used as a
dimensionality reduction step for visualizing scRNA-seq
data in two dimensions. A typical scRNA-seq analysis by
Luecken and Theis502 serves as a strong example of best
practices for this technique.
►► Computational and analytical challenges in single-cell
transcriptomics.291
►► Scater: pre-processing, quality control, normalization
and visualization of single-cell RNA-seq data in R.503
►► SCnorm: robust normalization of single-cell RNA-seq
data.504
►► Integrating single-
cell transcriptomic data across
different conditions, technologies, and species.505
►► SCANPY: large-scale single-cell gene expression data
analysis.506
►► Performance assessment and selection of normalization procedures for single-cell RNA-seq.507
►► Falco: a quick and flexible single-
cell RNA-
seq
processing framework on the cloud.508
►► Dimensionality reduction for visualizing single-
cell
data using UMAP.509
►►
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►►
►►

Visualization and analysis of single-cell RNA-seq data
by kernel-based similarity learning.510
Current best practices in single-cell RNA-seq analysis:
a tutorial.502

Multiparameter cytometric data analysis
One of the main goals of multiparameter cytometry data
analysis is to identify the proportion of immune cell subpopulations (eg, memory CD8+ T cells, Th1 cells, and so on)
and their properties (eg, expression of activation markers
or cytokines, antigen-specificity of T cells, and so on).
Analysis of flow cytometry data starts from data preprocessing (compensation, batch effect assessment and
removal, curation of data sets, and exclusion of dead cells
and doublets) followed by placing the ‘gates’ to identify
cell subsets and obtain property information of those
subsets. Postprocessing entails comparison of groups and
aims to find significantly altered subpopulations of cells
with appropriate statistical methods.
►► Guidelines for the use of flow cytometry and cell
sorting in immunological studies.511
Traditionally, flow cytometric data are manually
analyzed using a dedicated software with a graphical user
interface, for example:
512
►► https://www.flowjo.com/
513
►► https://www.denovosoftware.com/
►► h t t p s : / / w w w .  a c e a b i o .  c o m /  p r o d u c t s /
novoexpress-software/514
515
►► https://www.vsh.com/products/winlist/index.asp
►► https://www.miltenyibiotec.com/US-en/products/
macs-  f low-  c ytometry/  s oftware/  f lowlogic-  s oftware.
html516
►► https://www.  b eckman.  c om/  f low-  c ytometry/  s oftware/kaluza517
Similar to flow cytometry data analysis, mass cytometry
data also require preprocessing (eg, transformation of ion
counts, normalization and batch correction, and so on).
365
►► The anatomy of single cell mass cytometry data.
Recent developments in both multiparameter flow
and mass cytometry enable the interrogation of up to 40
parameters at the single cell level. This high dimensionality requires sophisticated computational approaches
when analyzing data to gain worthwhile insights from
information-rich data sets. As the list of available analysis
tools continues to grow, it is worthwhile to start from a
high-level overview. There are supervised and unsupervised approaches. We will cover unsupervised approaches
first, followed by supervised approaches.
The most commonly used unsupervised analyses are
nicely summarized here.
►► Algorithmic tools for mining high-dimensional cytometry data.518
►► Computational flow cytometry: helping to make sense
of high-dimensional immunology data.519
►► The end of gating? An introduction to automated
analysis of high dimensional cytometry data.520
Unsupervised approaches for multiparametric flow or
mass cytometry have a significant overlap with those for

single-cell NGS data sets. In general, these can be classified as (1) data visualization, (2) cell type identification,
(3) differential analysis, and (4) network and multiomics
data integration.
►► A beginner’s guide to analyzing and visualizing mass
cytometry data.521
►► Computational approaches for high-
throughput
522
single-cell data analysis.
►► Advancing systems immunology through data-driven
statistical analysis.523
►► Mass cytometry: a powerful tool for dissecting the
immune landscape.524
While most analysis tools are written in open source
programing languages such as R, Python, or others, fee-
based platform services are available for multiparametric
cytometry data.
525
►► https://www.cytobank.org/
526
►► https://www.astrolabediagnostics.com/
Benchmark assessment of algorithms is a helpful
resource when deciding what algorithms to use, although
it is recommended to use multiple algorithms to ensure
the validity of analysis results.
►► Critical assessment of automated flow cytometry data
analysis techniques.527
►► Comparison of clustering methods for high-
dimensional single-
cell flow and mass cytometry
data.528
A supervised approach is also useful if population and
biomarker candidates are well defined with the traditional cascaded gating strategy. In this case, automated
gating reduces both interanalysts’ variabilities and time
spent for manual gating.
529
►► Flow cytometry bioinformatics.
►► Standardizing flow cytometry immunophenotyping
analysis from the human immunophenotyping
consortium.530
►► A standardized immune phenotyping and automated
data analysis platform for multicenter biomarker
studies.531
►► Implementation and validation of an automated
flow cytometry analysis pipeline for human immune
profiling.532
Software and tools for function and pathway analysis
Functional enrichment and pathway analysis are essential tasks for the interpretation of gene lists derived
from large-scale genetic, transcriptomic and proteomic
studies. Two of the most popular resources for understanding high-level functions and utilities of the biological system are the Kyoto Encyclopedia of Genes and
Genomes (KEGG) and BioCarta. A comprehensive
list of available tools is provided at the Gene Ontology
website. ImmuneSigDB is a comprehensive compendium of 5000 gene sets pertaining to immune biology,
which may provide the systems immunologist with a
useful resource for analysis of gene expression in the
immune system.
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http://www.geneontology.org533
534
►► KEGG: Kyoto Encyclopedia of Genes and Genomes.
►► The Gene Ontology (GO) database and informatics
resource.535
►► Compendium of immune signatures identifies
conserved and species-specific biology in response to
inflammation.536
Genomic, proteomic, and metabolomic data typically
result in lists of interesting genes or proteins. Translating
these gene sets into an understanding of the underlying
biological mechanism is a fundamental need in biological research. A popular resource that can help unravel
the mechanism behind a specific set of mutations is the
Database for Annotation, Visualization, and Integrated
Discovery (DAVID). Pathway Commons is another tool
used by computational biologists to download custom
subsets of pathway data for analysis, or to incorporate
powerful biological pathway and network information
retrieval and query functionality into websites and software. One widely used commercial product is Ingenuity
Pathway Analysis, which allows the user to access many
different algorithms to identify the most significant pathways and discover potential novel regulatory networks
and causal relationships associated with experimental
data.
537
►► DAVID: https://david.ncifcrf.gov
►► Pathway Commons: http://www.
pathwaycommons.
org/pc2538
►► DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract
biology from large gene lists.539
►► Pathway Commons, a web resource for biological
pathway data.540
►► Causal analysis approaches in Ingenuity Pathway
Analysis.541
Gene set enrichment analysis (GSEA) is a computational method that determines whether a specific set of
genes shows statistically significant, concordant differences between two biological states. The gene-
level
statistics for all genes in a pathway are aggregated into
a single pathway-level statistic. Finally, statistically significant pathways can be identified. The tools for this kind
of analysis are distributed as either stand-alone desktop
applications or as packages for R (eg, R-GSEA). Gene
set analysis (GSA) is an R function that differs from
GSEA in its use of the ‘maxmean’ statistic, which is often
more powerful than the modified Kolmogorov-Smirnov
statistic used in GSEA. GSA can also handle more than
two groups, such as multiple classes, survival times, and
quantitative outcomes. Both GSEA and GSA approaches
can help identify the most promising pathways or gene
sets to be used as predictive or prognostic biomarkers in
immunotherapy.
►► Ten years of pathway analysis: current approaches and
outstanding challenges.542
►► Gene set enrichment analysis: a knowledge-
based
approach for interpreting genome-
wide expression
profiles.543
►►
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►►
►►

Exploring gene expression data with class scores.544
On testing the significance of sets of genes.545

Conclusions
The advancement of high-throughput technologies has
provided an unprecedented opportunity to conduct
comprehensive analyses of genes, transcripts, proteins,
and other significant biological molecules for biomarker
identification. However, it has also complicated the
process of finding meaningful markers from these
complex data sets. It is time-consuming and challenging
to validate the accuracy of each step involved in the analysis workflow. In order to obtain reproducible results,
it is imperative to harmonize not only sample preparation and assay execution protocols but also data analysis
procedures.
Many software packages and pipelines have been
developed that have allowed us to effectively process
WES/RNA-
seq data and multiparameter cytometry
data, as well as to perform gene set/pathway analyses.
However, depending on the methods used in each data
processing and analysis step, substantially different
results and conclusions may be developed from
the same data set. These results should be assessed
and validated carefully with different methods and
experiments.
In vivo imaging (non-invasive and whole body)
Strict anatomical imaging criteria may be insufficient
to cover the spectrum of response to immunotherapy.
Updated immune-related response criteria are required
that incorporate imaging patterns observed with
immunotherapy.
►► Guidelines for the evaluation of immune therapy
related response
activity in solid tumors: immune-
criteria.546
►► Personalized tumor response assessment in the era
of molecular medicine: cancer-specific and therapy-
specific response criteria to complement pitfalls of
RECIST.547
Tumor metabolic processes precede structural
changes in anatomical imaging and as such may
provide sensitive indicators of early response to
therapy. It remains a challenge, however, to distinguish between neoplasms and infectious or inflammatory processes. This is particularly problematic in the
midst of irAEs.
►► Ipilimumab-induced
immune-mediated
adverse
18
events: possible pitfalls in
F-FDG-PET/CT
interpretation.548
►► Bacillus Calmette-
Guerin injections for melanoma
immunotherapy: potential for a false-positive PET/
CT.549
There are relatively few clinical trials involving immunotherapy that include molecular imaging, but those that
do target immune cells or functional markers.
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Imaging cytotoxic lymphocytes
Synthesis
of
2’-deoxy-2’-[18F]fluor-9-beta-D-
arabinofuranosylguanine: a novel agent for imaging
T cell activation with PET.550
►► Molecular imaging of lymphoid organs and immune
activation by positron emission tomography with a
new 18F-labeled 2’-deoxycytidine analog.551
►► Noninvasive detection of therapeutic cytolytic T cells
with 18F-FHBG PET in a patient with glioma.552
►►

Imaging immunosuppressive factors and cells
TGF-β antibody uptake in recurrent high-
grade
glioma imaged with 89Zr-fresolimumab PET.553
►► Clinical applications of iron oxide nanoparticles for
magnetic resonance imaging of brain tumors.554
►► Antibody positron emission tomography imaging in
anticancer drug development.555
Preclinical studies continue to explore molecular
imaging probes that enable visualization of immune
responses within tumors. Immuno-PET, the use of antibodies or antibody fragments to target PET radionuclides, introduces increased specificity to imaging, with
new probes appearing with increasing frequency.
►► An effective immuno-PET imaging method to monitor
CD8-dependent responses to immunotherapy.556
Antibody engineering optimizes in vivo pharmacokinetics and provides improved blood clearance for imaging
at early timepoints with high tissue specificity.
►► Engineered antibody fragments for immuno-
PET
imaging of endogenous CD8+ T cells in vivo.557
►► Targeting T and B lymphocyte with radiolabeled antibodies for diagnostic and therapeutic
applications.558
559
►► Noninvasive imaging of immune responses.
Immuno-PET probes targeted to cytokines (eg, IL-1β
and IFN-γ) show increased tissue specificity over probes
targeted at immune cell types that show significant uptake
in secondary lymphoid tissues.
►► Immuno-PET of innate immune markers CD11b and
IL-1β detect inflammation in murine colitis.560
►► IFN-γ PET Imaging as a predictive tool for monitoring
response to tumor immunotherapy.561
Radiolabeling of anti-PD-L1 antibodies and small non-
antibody therapeutics allows for the in vivo distinction of
PD-L1 positive and negative tumors.
►► Noninvasive imaging of tumor PD-
L1 expression
using radiolabeled anti-PD-L1 antibodies.562
►► Engineering high affinity PD-1 variants for optimized
immunotherapy and immuno-PET imaging.563
Given the intensity of work on CAR T cell therapy,
significant efforts are underway to generate reporter
systems to track the distribution, persistence, and in situ
function of transferred T cells.
18
►► [ F]FHGB PET/CT imaging of CD34-
TK75 transduced donor T cells in relapsed allogeneic stem cell
transplant patients: safety and feasibility.564
►► Quantitative imaging of the T cell antitumor response
by positron-emission tomography.565
►►

Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo.566
Finally, a growing mechanistic understanding of T cell
metabolism in TME enables in vivo quantification of
effector T cell accumulation pretherapy and post-therapy
through metabolite detection.
►► Lactate chemical exchange saturation transfer
(LATEST) imaging in vivo a biomarker for LDH
activity.567
►► Molecular
imaging biomarkers for cell-
based
immunotherapies.568
►►

Conclusions
Molecular imaging allows non-invasive profiling of whole
primary tumors, distal metastases, and involved lymph
nodes, potentially aiding patient selection for given therapies and evaluation of response. Molecular imaging is
just starting to be used to monitor therapy in immuno-
oncology, and preclinical models indicate the potential
to monitor specific cellular processes in a longitudinal
manner independent of biopsy bias.
Predictive metabolic biomarkers in tumor immunotherapy
While select metabolic enzymes and their byproducts have
been investigated as prognostic biomarkers in various
cancers, the use of metabolic biomarkers as predictive guides for cancer immunotherapy is an emerging
concept that is currently in its infancy. There is a significant amount of evidence supporting the role of the metabolic enzyme, indoleamine 2,3-dioxygenase (IDO-1), in
immune tolerance. However, the ECHO-301/KEYNOTE252 study recently showed no significant improvement in
the clinical outcome of patients with stage IV melanoma
with the addition of the IDO-1-selective inhibitor, epacadostat, to pembrolizumab (anti-PD-1 antibody) compared
with pembrolizumab alone. In addition to the emerging
field of immunometabolism and the realization that metabolic pathways play critical roles in directing immune
cell function, the results of this clinical trial support the
need for additional studies designed to identify metabolic
biomarkers capable of predicting responses to immunotherapeutic combination regimens.
Tryptophan-degrading enzymes
The metabolic by-products of tryptophan (Trp) degradation including kynurenine (kyn) have been implicated as playing an important role in the generation of
immune tolerance. Given that IDO-1 is upregulated in
more inflamed environments due to its regulation by IFN
signaling, expression levels often correlate with PD-L1
expression and numbers of infiltrating CD8+ T cells. As
a result, several studies have found positive associations
between IDO-1 expression and response to checkpoint
blockade.
►► A prospective phase II trial exploring the association between tumor microenvironment biomarkers
and clinical activity of ipilimumab in advanced
melanoma.141
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An immune-
active tumor microenvironment favors
clinical response to ipilimumab.569
►► High IDO-1 expression in tumor endothelial cells is
associated with response to immunotherapy in metastatic renal cell carcinoma.570
These data seemingly contradict additional studies
that have also linked IDO-1 expression by certain tumor
models with resistance to anti-CTLA-4 antibody immunotherapy. Consistent with this finding, IDO-1 can
promote the recruitment of myeloid-derived suppressor
cells (MDSCs), making these tumors more susceptible to
agents blocking MDSC recruitment.
►► Indoleamine 2, 3-
dioxygenase is a critical resistance
mechanism in antitumor T cell immunotherapy
targeting CTLA-4.571
►► Targeting myeloid-
derived suppressor cells with
colony stimulating factor-1 receptor blockade can
reverse immune resistance to immunotherapy in
indoleamine 2,3-dioxgenase-expressing tumors.572
The IDO-1 enzyme converts Trp to a series of metabolic by-
products including kyn. While this process
starves effector T cells of the essential amino acid Trp
and suppresses their proliferation, kyn drives regulatory
T cell differentiation and promotes immune tolerance.
Indeed, the following reference describes serum kyn/
Trp ratios and quinolinic acid concentrations based on
high-
performance liquid chromatography-
mass spectrometry (HPLC-MS) and MS analyses as being associated
with diminished PFS in patients with NSCLC undergoing
nivolumab (anti-PD-1 antibody) immunotherapy.
►► Can IDO activity predict primary resistance to anti-
PD-1 treatment in NSCLC?.573
Notably, these data are also consistent with a recent
study demonstrating that adaptive increases in serum kyn/
Trp ratio are associated with inferior OS in patients with
advanced melanoma and RCC undergoing nivolumab
immunotherapy.
►► Metabolomic adaptations and correlates of survival to
immune checkpoint blockade.574
►►

Adenosine
Adenosine is an immunosuppressive nucleoside that
has been demonstrated to negatively regulate antitumor
immunity by directly suppressing effector T cell and
NK cell functions. CD73 is an ecto-5’-nucleotidase that
controls levels of adenosine in the TME by catalyzing
the breakdown of adenosine monophosphate (AMP).
Preclinical studies indicate that tumor expression of
CD73 is associated with inferior responses to checkpoint inhibitor immunotherapy and increased responsiveness to the inhibition of adenosine signaling. CD73
can also be cleaved from the cell surface and found
in the serum. Recent work has shown that the enzymatic activity of soluble CD73 in the serum correlates
with response to nivolumab in patients with metastatic
melanoma.
►► Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.575
42

►►

►►

Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T cell
responses.576
Soluble CD73 as biomarker in metastatic melanoma
patients treated with nivolumab.577

Tumor glycolysis and oxidative phosphorylation
The metabolic landscape of the TME has been shown to
contribute to immunotherapy resistance in a variety of
contexts. The elevated glycolytic capacity of malignant
tissues has been associated with T cell glucose starvation
and diminished antitumor immune responses. Indeed,
circulating levels of LDH, which may serve as a surrogate
for glycolytic levels in the TME, also correlate with inferior responses to checkpoint inhibitor therapy.
►► Increased tumor glycolysis characterizes immune
resistance to adoptive T cell therapy.578
►► Targeting
tumor-
associated acidity in cancer
immunotherapy.579
Other studies have indicated that the process of oxidative phosphorylation can also be associated with resistance to anti-PD-1 blockade in both melanoma cell lines
and clinical melanoma specimens.
►► Tumor cell oxidative metabolism as a barrier to PD-1
blockade immunotherapy in melanoma.580
Oxidative phosphorylation of tumors has been associated with the development of tumor hypoxia, a process
that has also correlated with resistance to pembrolizumab
immunotherapy in preclinical models and patients with
advanced melanoma.
►► Genomic and transcriptomic features of response to
anti-PD-1 therapy in metastatic melanoma.166
►► Efficacy of PD-1 blockade is potentiated by metformin-
induced reduction of tumor hypoxia.581
Fatty acid oxidation (FAO) drives oxidative phosphorylation and in local myeloid cells within the TME this
process may contribute to tumor-
mediated immune
evasion. Consistent with an important role for FAO
in the regulation of tumor immunity, the genetic
silencing and systemic pharmacological inhibition of this
pathway in preclinical models enhance the efficacy of
immunotherapy.
►► Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor
cells and enhances cancer therapies.582
►► Paracrine
Wnt5a-β-catenin signaling triggers
a metabolic program that drives dendritic cell
tolerization.583
Conclusions
In light of the emerging data highlighting the critical
role of cellular metabolism in the regulation of antitumor immunity, the role of metabolic biomarkers in the
development of novel immunotherapy strategies is likely
to expand. The development of methods to more readily
study in situ metabolic biomarkers in a cell type-specific
manner would greatly facilitate the use of metabolic
biomarkers in clinical trial development.
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Table 2 Online resources: tools for the bench and other useful websites
Resource

Description

URL link

CIMAC/CIDC
network

The Cancer Immune Monitoring and Analysis Centers (CIMAC) and the Cancer Immunologic Data Commons (CIDC) are NCI-
funded academic centers for advanced clinical trial immune monitoring.

https://cimac-network.org/

PACT

The Partnership for Accelerating Cancer Therapies (PACT) is a public–private collaboration that extends the CIMAC/CIDC
activities to include additional non-NCI clinical trials.

https://fnih.org/what-wedo/programs/partnershipfor-accelerating-cancertherapies

Links to FDA
biomarker
approval

The FDA’s Center for Drug Evaluation and Research works with stakeholders to identify and develop new biomarkers, review
biomarkers for use in regulatory decision-making, and qualify biomarkers for specific contexts of use.

https://www.fda.gov/
drugs/drug-developmenttool-qualificationprograms/cder-biomarkerqualification-program

Public
databases

ImmPort is a data repository and sharing tool built by NIAID for immunology-related assay data of various types.

http://www.immport.org

The Cancer Genome Atlas is a database of sequences from over 20,000 cancer and matched normal tissues.

https://portal.gdc.cancer.
gov

Transcription
factors
binding sites
prediction
software

Transcription factor (TF) binding site prediction is very important in deciphering gene regulation at a transcriptional level. TF
binding sites are typically identified by either matching to a consensus sequence or using position-specific scoring matrices
(PSSMs). PSSMs can be obtained from resources including the commercial transcription factor database (TRANSFAC) and the
open access database JASPAR:
►► Computer methods to locate signals in nucleic acid sequences.584
►► TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes.585
►► JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles.586
In 2005, Tompa M et al587 evaluated 13 algorithms designed to identify cis-regulatory sites using TF binding sites from
TRANSFAC. Their results revealed that the Weeder algorithm performed best:
►► Assessing computational tools for the discovery of transcription factor binding sites.587
A set of de novo motif discovery tools, namely rGADEM (R-based genetic algorithm-guided formation of spaced dyads coupled
with an expectation-maximization (EM) algorithm for motif discovery), HOMER (hypergeometric optimization of motif enrichment),
MEME-ChIP (multiple EM for motif elicitation-chromatin immunoprecipitation), and ChIPMunk (a modification of the classical EM
approach), were also evaluated using ChIP-seq data ENCODE. The study showed that rGADEM was the best-performing tool
for creating PSSMs from high-throughput ChIP-seq data. FIMO (Find Individual Motif Occurrences) and MCAST (Motif Cluster
Alignment and Search Tool) were the best-performing TF binding site prediction tools for scanning PSSMs against DNA:
►► Evaluating tools for transcription factor binding site prediction.588

Tools for
neoantigen
prediction

Neoantigens are small peptides derived from mutated proteins in cancer cells that can be recognized as foreign by immune cells IEDB: http://tools.iedb.
and trigger an immune response. There are many challenges in computational methods/tools to identify neoantigens and to
org/main/datasets
predict which may serve as optimal targets for the development of immunotherapy approaches:
589
►► Neoantigens in cancer immunotherapy
►► Computational genomics tools for dissecting tumour-immune cell interactions.590
►► Applications of immunogenomics to cancer.490
MHC binding has been considered a necessary step for neoantigens to be recognized by T cell receptors. The MHC binding
prediction methods can be categorized as binding motif-based, position-specific score-based or matrix-based, and machine
learning-based, such as artificial neural networks (ANN) or support vector machines. Because of the polymorphic nature of MHC
class II molecules and variations in accepted peptide length, the prediction results for MHC class II binding are less accurate than
those for MHC class I. Many existing MHC binding peptide and T cell epitope databases could potentially serve as a training data
pool to develop prediction models. A good example is the Immune Epitope Database (IEDB), which provides a comprehensive
resource for experimental data on antibody and T cell epitopes studied in multiple diseases:
►► SYFPEITHI: database for MHC ligands and peptide motifs.591
►► Profile analysis: detection of distantly related proteins.592
►► Gapped sequence alignment using artificial neural networks: application to the MHC class I system.593
►► NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and
peptide length datasets.594
►► NetMHCpan, a method for MHC class I binding prediction beyond humans.595
►► Application of support vector machines for T-cell epitopes prediction.596
►► SVMHC: a server for prediction of MHC-binding peptides.597
►► The immune epitope database and analysis resource: from vision to blueprint.598
►► The immune epitope database (IEDB) 3.0.599
►► IEDB: http://tools.iedb.org/main/datasets600
Not all MHC binding peptides are immunogenic. Combination approaches have been developed to use additional information
(eg, proteasome cleavage) in order to reduce the false positive rate. Since the stability of the peptide–MHC interaction has
experimentally been shown to be more strongly correlated to T cell immunogenicity, netMHCstabpan (pan-specific prediction
of peptide–MHC class I complex stability) uses a neural network approach based on a data set of stability values calculated for
different peptide–MHC class I complexes, rather than their binding affinity values:
►► Pan-specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity.601
Many pipelines have been developed for neoantigen prediction from WES sequencing data via integration of multiple methods.
For example, MuPeXI (mutant peptide extractor and informer) is a program to identify tumor-specific peptides from sequencing
data and assess their potential to be neoantigens. The peptides are sorted according to a priority score which is intended to
roughly predict immunogenicity. A flexible, streamlined computational workflow for identification of personalized Variant Antigens
by Cancer Sequencing (pVACSeq) integrates tumor mutation and expression data:
►► MuPeXI: prediction of neo-epitopes from tumor sequencing data.602
►► pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens.603

CTRs

►► USA: https://www.clinicaltrials.gov
►► Europe: https://www.clinicaltrialsregister.eu/

ANN, artificial neural networks; CIDC, Cancer Immunologic Data Commons; CIMAC, Cancer Immune Monitoring and Analysis Centers; CTR, clinical trial registry; EM, expectation maximization; FDA, Food and Drug
Administration; FIMO, Find Individual Motif Occurrences; HOMER, hypergeometric optimization of motif enrichment; IEDB, Immune Epitope Database; MCAST, Motif Cluster Alignment and Search Tool; MHC, major
histocompatibility complex; MuPeXI, mutant peptide extractor and informer; NCI, National Cancer Institute; NIAID, National Institute of Allergy and Infectious Diseases; PACT, Partnership for Accelerating Cancer
Therapies; PSSM, position-specific scoring matrix; pVACSeq, peronsalized Variant Antigens by Cancer Sequencing; rGADEM, R-based genetic algorithm-guided formation of spaced dyads coupled with an EM
algorithm for motif discovery; TF, transcription factor; WES, whole exome sequencing.
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